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Compared to general-used tissue biopsy, less invasive “liquid biopsy” can provide insight which 
related to the real-time dynamics of cancer by more frequent analysis of circulating biomarkers 
including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Furthermore, liquid 
biopsy is expected to offer a more comprehensive information of the disease, because circulating 
biomarkers may include cancer-associated materials from multiple disease sites in the body. However, 
the extreme rarity of cancer-associated circulating biomarkers in blood has been a great challenge to 
the achievement of the goals for liquid biopsy. 
CTC refers to tumor cell which disseminate from the primary tumor site to blood stream. Although 
CTC enumeration provides potential utility as a promising prognostic liquid biopsy marker, it has not 
been established yet due to its extreme rarity in comparison to other types of blood cells (1–10 CTCs/106 
blood cells in 1 mL of blood). Representatively, CellSearch has been approved by the FDA about CTC 
enumeration system for breast, colorectal, and prostate cancer testing. And various microfluidic chips 
have been developed for CTC isolation based on physical and biochemical characteristics of CTCs. For 
example, some chips used epithelial cell adhesion molecule (EpCAM) antibody based capture and 
others used a size-selective manner. Many clinical papers were reported about the role of CTCs 
according to the remarkable improvement of the device. Notably, a high CTC count is associated with 
poor prognosis for cancer patients. 
Despite the clinical importance and progress of CTC-based cancer diagnostics, most of the current 
methods of enriching CTCs are difficult to implement in general hospital settings due to complex and 
time-consuming protocols. Among existing technologies, size-based isolation methods provide 
antibody-independent, relatively simple, and high throughput protocols. However, the clogging issues 
and lower than desired recovery rates and purity are the key challenges. 
In this thesis, fluid-assisted separation technology (FAST), which applied to centrifugal microfluidics 
with size-based membrane filtration, was suggested to solve clogging issues. FAST was inspired by 
antifouling membranes with liquid-filled pores in nature and it achieved high sensitivity (95.9 ± 3.1% 
recovery rate) and high selectivity (>2.5 log depletion of white blood cells) without clogging. Moreover, 
rapid (>3 mL/min) isolation of viable CTCs from whole blood without prior sample treatment enabled 
simple and ultrafast process which could be applied in clinical field. Numerical simulation and 
experiments demonstrated that FAST disc achieved uniform, clog-free, ultrafast cell enrichment with 
pressure drops much less than in conventional size-based filtration, at 1 kPa. We validated the clinical 
utility of the point-of-care detection of CTCs with 142 cancer patients’ samples. 
For the depth study, we selected lung cancer to apply molecular analysis based on CTCs. In 
particularly, lung cancer is the most common cause of worldwide cancer-related mortality with 1.8 
million new cases reported every year in both men and women. NSCLC accounts for 85% of all lung 
cancers and epidermal growth factor receptor (EGFR) mutations are the representative mutation in 10-
30% of patients. According to the mutant type of NSCLC patients, targeted therapies including EGFR 
tyrosine kinase inhibitor (TKI) drugs can induce improved clinical outcomes. For obtaining molecular 
information about their tumors, detection of EGFR mutation from patient-driven CTCs should be 
validated through the confirmation of concordance with tissue biopsy results. 
Successive downstream analysis of single CTCs from each patient during treatment is needed for 
observing a change of characteristics related with therapeutic response. To make it possible, robust CTC 
isolation system with high efficiency is required. With the above needs in mind, we report the clinical 
validation and demonstration of a FAST disc capable of rapid CTC isolation and easy single cell picking 
for individual CTC characterization. We report here a proof-of-concept demonstration showing clinical 
meaning of CTCs included multigene expression as a monitoring marker in NSCLC. 
ii 
  
Table of Contents 
Abstract ................................................................................................................................................... i
Table of Contents .................................................................................................................................. ii 
List of Figures ....................................................................................................................................... iv 
List of Tables ....................................................................................................................................... xiii 
CHAPTER 1. Introduction .................................................................................................................. 1 
1.1 Liquid biopsy in non-small cell lung cancer ..................................................................... 1 
1.2 Technologies for CTCs analysis and clinical applications in NSCLC ............................ 7 
1.2.1 Prognosis using commercially available CTCs isolation devices ........................... 7 
1.2.2 Molecular diagnosis using isolated CTCs by microfluidic chips.......................... 11 
1.3 Research motivations ........................................................................................................ 15 
1.4 Research aims .................................................................................................................... 16 
CHAPTER 2. Developmet of clog-free CTC isolation disc in label-free manner .......................... 18 
2.1 Centrifugal microfluidics for size-based CTC isolation ................................................ 18 
2.1.1 Centrifugal microfluidics ......................................................................................... 18 
2.1.2 Membrane filtration ................................................................................................ 20 
2.2 Fluid assisted separation technology (FAST) disc for CTC enrichment ...................... 22 
2.2.1 Introduction .............................................................................................................. 22 
2.2.2 Experimental details ................................................................................................ 24 
2.2.3 Result and discussion ............................................................................................... 29 
2.2.4 Conclusions ............................................................................................................... 50 
CHAPTER 3. Single cell anaysis of isolated CTCs by using FAST disc ........................................ 52 
3.1 Introduction ....................................................................................................................... 52 
3.2 Prognostic values of CTCs through single cell analysis ................................................. 53 
3.2.1 Experimental details ................................................................................................ 53 
3.2.2 Results and discussion ............................................................................................. 56 




CHAPTER 4. General conclusions and future perspectives ........................................................... 87 
4.1 General conclusions .......................................................................................................... 87 
4.2 Plan for future ................................................................................................................... 88 
4.3 Future perspective ............................................................................................................ 89 
 
References…………………………………………………………………………..………………...90 
Acknowledgement ............................................................................................................................. 104 
iv 
  
List of Figures 
 
Figure 1.1. Schematic illustration of clinical utility of liquid biopsy for lung cancer. Circulating 
biomarkers (CTCs, and ctDNA) are used for the identification of actionable mutations such as 
sensitizing (exon 19 and 21) and resistant (T790M) EGFR mutations. ……………………………... 2 
 
Figure 1.2. Examples of CTC isolation chips used for the mutation analysis of CTCs from patients with 
NSCLC. (A) HbCTC-Chip, which has a herringbone pattern on the channel roof, was developed to 
improve capture efficiency (Right : 1”  3” glass slide)33,34; (B) The purity of the cells captured by 
NanoVelcro chip, which has silicon nanowires on its bottom substrate to maximize the surface bound 
antibody, were further improved by thermoresponsive purification step36; (C) A microfluidic device 
(3.5 cm  2.5 cm PDMS chip) capable of single-cell isolation and retrieval was developed to improve 
purity37; (D) A nanowell array filled with CTCs magnetically captured by a dense array of magnetic 
pores (MagSifter) were used for multigene expression profiling from individual CTCs (Upper scale bar: 
200 μm, lower scale bar: 50 μm)38,39; (E) OncoBean Chip, which has bean-shaped posts coated with 
antibodies were developed to improve the throughput (Right: 2”  3” glass slide)40,41. Reproduced 
from ref. (33-41) with permission from the United States National Academy of Sciences, American 
States National Academy of Sciences, American Chemical Society, Nature Publishing Group, Royal 
Society of Chemistry, and Wiley-VCH. ………………………………………………………………13 
 
Figure 2.1. Microfluidic systems, lab-on-a-chip and lab-on-a-disc. (a) Image of miniaturized lab-
on-a-chip (46). (b) Image of operating system of lab-on-a-chip (47). (c) Scheme of lab-on-a-disc and 
operation system (48). (d) Forces acting in a spinning system (49). …………………………………19 
 
Figure 2.2. Scheme of membrane filtration. (a) Dead-end filtration (normal flow filtration) with cake 
layer. (b) Tangential-flow filtration (cross-flow filtration). (c) Insertion of memrane into the lab-on-a-
disc for taking the advantage of tangential-flow filtration. ……………………………………..……21 
 
Figure 2.3. Design and function of the FAST disc. (a) Schematic illustration showing the mechanism 
of the Fluid-Assisted Separation Technology (FAST) disc. The pressure required to force a blood sample 
(red) through a membrane with liquid-filled pores (FAST) is expected to be much lower than that 
required to achieve transport through a bare membrane (non-FAST). The filtration occurs mainly in the 
v 
  
outer rim of the filter with a disc spinning in non-FAST mode, whereas a more uniform transport of 
liquid takes place with the FAST disc, as demonstrated in the images showing 10 μm red fluorescent 
beads filtered with the conventional (top) and FAST (bottom) methods. (Scale bar: 100 μm) (b) Images 
of lab-on-a-disc and portable operation system. The track-etched polycarbonate membrane with 8 μm 
pores was employed for the CTC isolation.………………………………..……….…………….…. 23 
 
Figure 2.4. Expanded view of the FAST disc. A FAST disc is composed of 4 polycarbonate plates and 
3 layers of pressure sensitive adhesive (PSA) tape sandwiched between the plates. The track-etched 
membrane is then assembled with detachable parts including o-rings, gaskets, holders, and a back plate 
using a bolt and nut.…………….......................... .......... .......... ............................…………….…… 30 
 
Figure 2.5. Images showing the experimental procedure for CTC isolation from whole blood using the 
FAST disc system. (a) 3 mL of whole blood was injected into the FAST disc without any prior sample 
treatment. (b) The disc was loaded into the custom-designed operation machine and (c) filtration was 
conducted by spinning the disc according to the preloaded spin program. (d) After CTC capture and 
immunostaining on the disc, the membrane was removed and mounted on a slide glass for imaging and 
storage.……………………………………………………………………………………………… 31 
 
Figure 2.6. Distribution of the particles on the membrane after filtration. A suspension of fluorescent 
polystyrene particles with a diameter of 10 μm was filtered by spinning the disc at 600 rpm in 
conventional (non-FAST) and FAST mode. (a) The particle distribution was analyzed as a function of 
the radial position. (b) Image analysis shows that only part of the total area is used for filtration in non-
FAST mode while more uniform filtration occurs in FAST mode. …………………………….……32 
 
Figure 2.7. Effect of the FAST on the pressure drop, filtration time, and recovery of c
ancer cells from whole blood. (a) Schematic diagram and a photo image of a disc for 
the wireless measurement of the transmembrane pressure while the disc was being spu
n at 600 rpm to filter the whole blood. A pressure sensor was connected to a data ac
quisition board and the obtained data were transmitted to a computer by a Bluetooth 
module equipped with a data acquisition board. (b) Pressure drop and (c) Decanting v
olume measured during the filtration of whole blood as a function of time. Use of the 
FAST disc enables ultrafast (< 20 s for 3 mL of whole blood) CTC isolation with a r
educed pressure drop (~1 kPa). (d) The recovery of MCF-7 cells spiked in whole bloo
d showed a 95.9% efficiency with a good linearity for the FAST disc, compared to 5
vi 
  
4.0% in the non-FAST case. ……………………………………………………………………. 35 
 
Figure 2.8. Numerical analysis comparing non-FAST and FAST disc methods. (a) Blood phase 
flows (left) and pressure contours (right) at 0.13 s, induced by centrifugal force generated by 
spinning the disc at 600 rpm in non-FAST (top) and FAST (bottom) modes. Pressure is 
developed due to centrifugal force in O (1 kPa), which is determined by the mass of the liquid 
phases and the angular velocity of rotation. In the non-FAST case, the pressure gradient in the 
upper chamber causes a non-uniform pressure drop across the membrane and, in consequence, 
the blood phase is filtered only through a small portion of the membrane. This significantly 
reduces the efficiency of the membrane. Meanwhile, in the FAST disc, the chamber under the 
membrane is filled with an aqueous phase during the entire filtration process. Therefore, when 
the blood phase reaches the membrane, the blood phase flows into the lower chamber uniformly 
and diffuses into and mixes with the liquid phase. The FAST disc uses the entire membrane area 
for filtration which significantly alleviates clogging. (b) Pressure plots in the radial direction 
above (1) and below (2) the membrane. (c) Pressure difference (∆p = p1 – p2) along radial 
direction. The broken lines correspond to the non-FAST cases (b,c) indicate those locations 
where liquid flow does not occur. …………………………………………………………………. 36 
 
Figure 2.9. Electric circuit equivalent model for non-FAST and FAST methods. Electric circuit 
equivalent models for (a) non-FAST and (b) FAST methods. (c) Effect of outlet resistance (R2) in non-
FAST method, which varies with the channel width. If the outlet resistance is too low (blue line), back 
flow may be possible, making system unstable. If the outlet resistance is too high (black line), the flow 
rate is significantly reduced. (d) Capacitance effect of lower chamber in non-FAST method. If the 
capacitance increases, the flow rate of the outlet stabilizes. If there is no air in the lower chamber (FAST 
method), the flow is almost incompressible and so can spontaneously respond to the flow rate while the 
system is running. These hydrodynamic behaviors should be considered to optimize the chamber 
configuration and fluid channels according to the operating conditions. . ………….………………. 37 
 
Figure 2.10. Optimization of the FAST disc using cancer cells spiked into whole blood. The 
capture efficiency (red); defined as number of captured cancer cells/input number of cancer cells, 
and purity (blue); log depletion ratio defined as log (input number of white blood cells 
[WBCs]/number of remaining WBCs on the membrane), were evaluated with MCF-7 cells 
spiked into whole blood at various (a) rotational speeds and (b) numbers of washing steps. The 
vii 
  
spin speed was held at 600 rpm and two washes were used for the follow-up experiments with 
cells spiked in whole blood. For the molecular analysis, six washes were used to achieve the 
>3.0-log depletion of WBCs. (c) Capture efficiency test with five cancer cell lines spanning a 
broad range of EpCAM expressions and sizes produced a > 96% capture efficiency with the 
FAST disc. (d) Reproducibility tests with spiked cells (10–100 MCF-7 cells) in whole blood 
conducted for fifteen days using 30 different discs showed 96.2 ± 2.6 % (mean ± SD) recovery. 
(e) Live/dead assay result for captured cells (AGS) on a FAST disc after being cultured for 15 
days show good viability. Scale bar: 100 m. ........…........…........…........…........…........…..…. 38 
 
Figure 2.11. EpCAM expressions and sizes of five cancer cell lines. (a) EpCAM expression as 
confirmed by real-time PCR and normalized to GAPDH. MDA-MB-231, MDA-MB-436 breast cancer 
cells and AGS stomach cancer cells exhibited a low expression while HCC78 lung cancer cells exhibited 
a high expression compared to MCF-7 breast cancer cells. (b) Cell diameters of various cell lines were 
measured; MDA-MB-231 (13.4 ± 3.3 μm), MDA-MB-436 (12.2 ± 1.5 μm), AGS (12.4 ± 1.7 μm), 
MCF-7 (12.7 ± 1.6 μm), HCC78 (16.4 ± 2.7 μm). The data was the mean ± S.D (n = 3).…………… 39 
 
Figure 2.12. Results of live/dead assay after the filtration and 15 days culturing. The cell viability (97.6 
± 0.4%) was confirmed immediately after filtration by live/dead assay. Images show that there are only 
live cells (a) and no dead cells (b). Scale bar: 20 μm. (c-f) Various kinds of cancer cells captured on the 
membrane by the FAST disc were incubated for 15 days. Images show the results of live/dead assay 
with the incubated cells of MDA-MB-231 (c), MDA-MB-436 (d), MCF-7 (e), and HCC78 (f). Scale 
bar: 100 μm. ........…........…........…........…........ ........…........ ........…........ ........…....…........…..…. 40 
 
Figure 2.13. Performance comparison with the commercially available size-based filtration 
system and clinical test of FAST disc. (a) Capture efficiency and purity were compared for the 
results of the filtration experiments with MCF-7 cells spiked in blood samples. Whole blood 
was directly filtered through membranes with 8.0 m pores with the FAST disc. The samples 
were diluted and prefixed according to the manufacturer’s recommended protocol for the 
ScreenCell Cyto device, and were then filtered through membranes with 7.5 m pores by the 
application of negative pressure provided by a vacuum tube. (b) Fluorescence images of isolated 
CTC obtained from a patient’s blood sample (Scale bar: 8 m). (c) Performance comparison 
with FAST disc and ScreenCell by using clinical samples obtained from patients with cancer of 
the breast (n = 3), stomach (n = 4), colon (n = 4), bile duct (n = 3), and lung (n = 2). All counts 
were normalized to 7.5 mL.  (d) Number of CTCs isolated from blood samples of healthy 
viii 
  
donors (H, n = 50), patients with cancer of the breast (B, n = 18), lung (Lu, n = 35), stomach (S, 
n = 76), bile duct (BD, n = 3) gallbladder (GB, n = 4), liver (Li, n = 3), and pancreas (Pa, n = 3). 
(e) Number of CTCs from lung cancer patients with/without distant metastasis was compared 
with healthy donors. (f) EGFR real-time PCR assay was performed using the cells captured on 
membrane from blood samples of two lung cancer patients with the L858R and 19-Del 
mutations. Blue line is for internal control and red line is for the target sample. Negative controls 
did not show any amplification signal.…………………………………………………...……… 42 
 
Figure 2.14. The fluorescence images of the membrane after the isolation of CTCs from the blood of a 
cancer patient. CTCs captured by size-based isolation using (a) FAST disc and (b) ScreenCell were 
immunostained. The blue, green, and red signals are from DAPI+, CK+ or EpCAM+, and CD45+ cells, 
respectively. The filter membranes were retrieved to acquire the fluorescence images. It is noted that 
the number of WBCs (DAPI+, EpCAM-, CK-, and CD45+) from a FAST disc is significantly smaller 
than that from ScreenCell. The circles in the left pictures show the whole area of the membrane with 
the diameter of 10 mm and 6 mm for a FAST disc and a ScreenCell, respectively. The red dot squares 
are zoomed to show an enlarged view of the corresponding area in the middle and right images. Scale 
bar is 2 mm, 300 μm and 100 μm from left to right, respectively.……………………..…………….. 43 
 
Figure 2.15. Prevalence of CTCs from patients with breast cancer (n = 18), stomach cancer (n = 76) 
and lung cancer (n = 35) (a) CTCs (mean: 58 CTCs/7.5 mL, median: 13 CTCs/7.5 mL, range: 0–540 
CTCs/7.5 mL) were detected from 83.3% (15/18) of breast cancer patients. (b) In the case of stomach 
cancer patients, 63 of the 76 samples (82.9%) contained CTCs within a range of 2–485 CTCs/7.5 mL 
(mean: 21 CTCs/7.5 mL, median: 4 CTCs/7.5 mL). (c) CTCs (mean: 10 CTCs/7.5 mL, median: 4 
CTCs/7.5 mL, range: 0–62 CTCs/7.5 mL) could be detected in 68.6% (24/35) of lung cancer 
patients.……...………………………………………………………………………………………. 45 
 
Figure 2.16. Examples of images of CTCs isolated from blood of patients with breast cancer, stomach 
cancer, and lung cancer. DAPI+, EpCAM/CK+, and CD45- cells are classified as CTCs. (Scale bar: 8 
m). .………………………………………………………………………………………………… 47 
 
Figure 3.1. Workflow, mechanism, and performance of FAST disc. (A) Visualization of the FAST disc 
before and after the CTC enumeration process. (B) The centrifugal force pushes the liquid in a tangential 
direction to the flow filtering through the membrane. (C) Size-based isolation of CTCs from whole 
ix 
  
blood (3 mL) can be completed within 1 min, all in one disc. After washing and staining for enumeration, 
the filter can be removed and mounted on a slide glass for downstream analysis. (D) Representative 
images of CTCs (DAPI+, EpCAM/CK+, CD45-) isolated from the blood of cancer patients. (E) 
Performance comparison between the CellSearch system and FAST disc using whole blood spiked with 
cancer cells (<100). Five cell lines with various EpCAM expression levels were used to quantify the 
recovery rates. (F) CTCs enumerated by the CellSearch system and FAST disc from the blood samples 
of 17 patients with different cancer types. (G) Reproducibility test using blood samples from one patient 
collected in two independent blood collection tubes showing similar CTC counts. ………………... 57 
 
Figure 3.2. Fluorescence images of patient-derived CTCs. Representative examples of (A) patient-
derived CTCs from two different NSCLC patients (Scale bar: 10 μm) and (B) CTC clusters from 
NSCLC patients (Scale bar: 8 μm). Merged images and three images from different fluorescent channels 
(DAPI, TRITC, and FITC) are shown. CTCs were defined as DAPI+/CD45-/CK+ or EpCAM+ 
cells .………………………………………………………………………………………………… 58 
 
Figure 3.3. Correlation between CTC counts and treatment responses on CT scans. (A) Kaplan-Meier 
curves for OS between two patient groups according to the cutoff baseline CTC count (66 CTCs/7.5 
mL). (CTCLow: n = 30, median OS: 18.04; CTCHigh: n = 8, median OS: 15.46, log-rank p = 0.3501; 
samples from two patients had a clogging issue.) (B) Six of 40 patients (15%) did not respond well to 
their first choice of therapy and had to change the treatment option more than once, resulting in a 
significantly poorer PFS than that of patients who responded well to the first-choice drug. Kaplan-Meier 
curves for PFS between two patient groups according to the number of treated drugs. (N = 1: n = 34, 
median PFS: 25.70, N > 1: n = 6, median PFS: 9.65, log-rank p = 0.0039). (C) Kaplan-Meier curves for 
OS between the two patient groups according to the number of treated drugs, demonstrating no 
significant difference. (N = 1: n = 34, median OS: undefined, N > 1: n = 6, median OS: 28.50, log-rank 
p = 0.7518).………………………………………………………………………………….……… 61 
 
Figure 3.4. Representative examples of CTC counts and CT images obtained during the course of 
treatment and their correlations. (A) Tumor size and CTC counts show an increase in the tumor burden 
during 582 days of various EGFR-TKI treatments for patient LP2. (B) Patient LP11 continued to receive 
erlotinib initially. The CTC counts from the blood draw at 301 and 378 days were significantly increased 
with PD determined from CT images obtained on days 294 and 378. After the treatment was changed 
to alimta, both the CTC counts and tumor burden decreased dramatically and PR was determined at day 
x 
  
462. (C) Relationships with the change rate of CTC counts, CTC (%); CTC counts change normalized 
by the baseline CTC, and CT scan image response results from patients with a 19 del mutation who 
enrolled in the follow-up monitoring study for more than 19 months. The CTC count change rate is 
sorted according to the imaging response results (PD or PR). The PD group showed a significantly 
greater CTC count change rate than the PR group (P = 0.011).……………………………...……… 63 
 
Figure 3.5. Procedures for single cell picking. (A) Schematic image of single cell picking. The 
membrane was separated from the disc and mounted onto the glass with the PDMS reservoir containing 
PBS. Using a capillary connected with a pump, a single cell was picked by the vacuum-assisted method. 
(B) Fluorescence images of a cell before and after picking from the membrane. DAPI+/CD45- stained 
cells are candidates for analysis. Image set of DAPI, CD45, and EpCAM before picking showing the 
target cells, and the other DAPI image shows the same spot after picking. (Scale bar: 10 μm).…… 65 
 
Figure 3.6. Gene expression profiles of single CTCs isolated from three patients with lung cancer and 
from lung cancer cell lines. (A) Heat map for the hierarchical clustering of the differentially expressed 
genes of single cells from four different NSCLC cell lines [H2228 (orange), H460 (purple), HCC78 
(brown), and PC9 (green)], WBCs (black), and CTCs from three patients [LP25 (red), LP38 (blue), and 
LP39 (cyan)]. Each row represents a single-cell sample. The scale bar indicates the Z-scores of gene 
expression values, with highly expressed genes depicted in red and low-expressed genes depicted in 
green. (B) Two-dimensional t-SNE analysis based on hierarchical clustering. Cells clearly grouped 
according to the sample source. (C) Gene expression data of individual cells were further characterized 
to show an epithelial or mesenchymal cell signature. Intra- and intercellular heterogeneity is 
demonstrated using four different NSCLC cell lines, and profiling of individual CTCs isolated from 
three patients with NSCLC patients before chemotherapy. Patients LP25 and LP39 carried an 19del 
mutation, and patient LP38 had the L861Q mutation.. ……………………………………………. 66 
 
Figure 3.7. Single-cell real-time PCR using various lung cancer cell lines. Single-cell mRNA 
expression of four lung cancer cell lines, H2228, H460, PC9, and HCC78, determined using 
BiomarkHD qRT-PCR. After picking individual cells captured on the membrane by a cell-picker, RNA 
was extracted and preamplified for single-cell mRNA expression analysis. Ct ≤ 30 with a Fluidigm real-
time PCR analysis software quality threshold of 0.65 was considered for the analysis. Columns and 




Figure 3.8. Single-cell real-time PCR using patient-driven CTCs from baseline samples and white 
blood cells. Single-cell mRNA expression of CTCs from three different patients at baseline (LP25, LP38, 
and LP39) determined using BiomarkHD qRT-PCR with five WBCs. Columns and rows show 
individual cells and the target genes assayed, respectively. N means no template 
control………………………………………………………………...……...…...…...…...…...…… 69 
 
Figure 3.9. Correlation matrix plots of correlations among 20 cells from four different cancer cell lines, 
five WBCs, and 30 patient-derived baseline CTCs isolated from three different patients. Spearman 
correlation coefficients for sample characteristics. High and low similarity is indicated with blue and 
red color based on the scale bar, respectively. The circle size represents the magnitude of the correlation. 
P-values in this correlation analysis were derived using the Cor.mtest function in R. Bonferonni 
correction was applied to P-values to account for multiple testing in the rank correlation 
matrix.…………………………………………………………………………………………..…… 72 
 
Figure 3.10. Summary of mesenchymal scores. (A) Distribution of mesenchymal scores from each 
sample according to the EMT characterization among four NSCLC cell lines and three NSCLC patients. 
Mesenchymal scores of single CTCs from patients (B) LP25 and (C) LP38 during TKI treatment. … 73 
 
Figure 3.11. Correlation of marker expression among four NSCLC cell lines. (A) Vimentin expression 
of five cells from each cell line according to the expression of epithelial markers EpCAM, KRT7, 18, 
and 19, respectively. (B) CD44 expression of five cells from each cell line according to the expression 
of epithelial markers EpCAM, KRT7, 18, and 19, respectively.……………………………...……… 74 
 
Figure 3.12. Longitudinal study of LP25 with CTC counts, individual CTC profile, and CT image 
response during TKI therapy. (A) Correlation between the number of CTCs and tumor size from CT 
images in patient LP25 with EGFR-mutant NSCLC during the course of TKI therapy. (B) Heatmap of 
the hierarchical clustering of gene expression profiles of single CTCs. (C) Three-dimensional t-SNE 
plots for CTCs isolated at three time points during the therapy of patient LP25. Despite the inter-sample 
heterogeneity of CTCs, cells clustered according to the same time point during the treatment. (D) EMT 
characterization of single CTCs from patient LP25 during TKI treatment.…………………...……… 76 
 
Figure 3.13. Longitudinal study of patient LP38 with CTC counts, individual CTC profile, and CT 
xii 
  
image response during TKI therapy. (A) Correlation between the number of CTCs and tumor size from 
CT images in patient LP38 with EGFR-mutant NSCLC during the course of TKI therapy. (B) Heatmap 
of the hierarchical clustering of gene expression profiles of single CTCs. (C) Three-dimensional t-SNE 
plots for CTCs isolated at three time points during the therapy of patient LP38. Despite the inter-sample 
heterogeneity of CTCs, the cells clustered according to the same time point during the treatment. (D) 
EMT characterization of single CTCs from patient LP38 during TKI treatment.….. .... .... ....……… 77 
 
Figure 3.14. Single-cell real-time PCR using CTCs from patient LP25 at various time points. Single-
cell mRNA expression was determined using BiomarkHD qRT-PCR. Columns and rows show 
individual cells and the target genes assayed, respectively. N means no template control.……….…. 78 
 
Figure 3.15. Single-cell real-time PCR using CTCs from patient LP38 at various time points. Single-
cell mRNA expression was determined using BiomarkHD qRT-PCR. Columns and rows show 
individual cells and the target genes assayed, respectively. N means no template control.…...……… 79 
 
Figure 3.16. Correlation matrix plots of CTCs before and after treatment in patient LP25. Spearman 
correlation coefficients for sample characteristics. High and low similarity is indicated with blue and 
red color based on the scale bar, respectively. The circle size represents the magnitude of the 
correlation.…………………………………………………………………………………...……… 81 
 
Figure 3.17. Correlation matrix plots of CTCs before and after treatment in patient LP38. Spearman 
correlation coefficients for sample characteristics. High and low similarity is indicated with blue and 





List of Tables 
 
Table 1.1. Advantages of liquid biopsy compared to tissue biopsy. ……...................... ......................... 2 
Table 1.2. Unique advantages and limitations of circulating biomarkers; CTCs vs ctDNA….............. 6 
 
Table 1.3. Examples of studies on CTCs-based prognosis for patients with NSCLC. ………………. 9 
 
Table 1.4. Summary of reports on mutation detection in CTCs from patients with NSCLC..……….. 12 
 
Table 2.1. Comparison of CTC detection in cancer patient’s blood using FAST disc and ScreenCell. 
CTCs were isolated from the blood of 16 cancer patients and the number of CTCs was normalized to 
7.5 mL (standard volume used by CellSearch system). …………………………………………….. 44 
 
Table 2.2. Number of CTCs isolated from blood samples of healthy donors and cancer patients. CTCs 
were isolated from blood samples of 50 healthy donors and 142 cancer patients and the number of CTCs 
was normalized to 7.5 mL (standard volume used by Cell Search system). ………….. .. .. .. .. ..…… 46 
 
Table.3.1 Patients demographics and clinical characteristics ………………………..……...………. 60 
 
Table.3.2 Detection of EGFR mutation from CTCs. The mutation detection results from CTCs isolated 
from total 13 patients were in 100% concordance with the corresponding results obtained from tissue 
biopsy sample. Notably, T790M, the acquired resistance EGFR mutation, detected at relapse (AR) of 
samples, but not before the treatment (BT), from two patients (LP49 and LP2) both from noninvasive 
blood-based CTC analysis as well as tumor biopsy.…………………………………………..………. 64 
 
Table 3.3. Genes used to profile single CTCs. 48.48 dynamic array microfluidic qRT-PCR chips 
(Fluidigm) used to confirm the expression of genes in all captured single cells.……………..………. 70
1 
  
CHAPTER 1. Introduction 
1.1 Liquid biopsy in non-small cell lung cancer 1 
Lung cancer has been the most common cause of cancer-related mortality in both men and women 
worldwide, with 1.8 million new cases in a year 1, 2. In contrast to the increase in survival rate for most 
other cancers, the 5-year relative survival still remains at 18% with an estimate of 158,040 deaths, which 
is about 26% of total cancer related death in 2017 for the USA alone. The highest mortality of lung 
cancer is partly because more than half of the cases are diagnosed at a distant stage, which the 5-year 
survival is only 4%. Therefore, there are critical needs to develop more sensitive technologies for early 
detection and to improve the survival rates of lung cancer. 
 
Non-small cell lung cancer (NSCLC) represents 85% of lung cancer, in which epidermal growth 
factor receptor (EGFR) mutations occur in 10–30% of NSCLC patients. Recent advances in 
understanding molecular abnormalities in lung cancer and highly sensitive molecular analysis 
technologies revealed that targeted therapies such as EGFR tyrosine kinase inhibitor (TKI) drugs can 
deliver improved clinical outcomes for certain groups of patients with advanced NSCLC 3-7. Currently, 
the tissue biopsy is conducted for most of the patients with NSCLC to obtain the molecular information 
of their tumors. However, the efficacy of the targeted therapy is limited because of the almost inevitable 
resistance development. The invasive nature of the tissue biopsy hinders frequent sampling to 
understand tumor dynamics and drug response. In addition, local sampling by tissue biopsy can be 
biased because of the heterogeneity of tumor and fail to detect the occurrence of metastasis at distant 
sites.  
 
Less invasive “Liquid Biopsy” can provide real time dynamics of lung cancer via more frequent 
analysis of circulating biomarkers such as circulating tumor cells (CTCs) and circulating tumor DNA 
(ctDNA). Furthermore, the liquid biopsy is expected to offer a more comprehensive picture of the 
disease because blood circulating markers may contain cancer associated materials from multiple 
disease sites of the body (Table 1.1). However, extreme rareness of tumor-associated biomarkers in 
blood has been a great challenge to achieve the desired goal. Recent innovations made in microfluidic 
chip-based ultrasensitive rare cell isolation technologies and affordable molecular detection 
technologies such as next generation sequencing (NGS) or droplet digital polymerase chain reaction  
* Chapter 1 is reproduced with the permission from “M. Lim†, C.-J. Kim†, V. Sunkara; M.-H. Kim; Y.-K. Cho, 





Table 1.1. Advantages of liquid biopsy compared to tissue biopsy 
Tissue biopsy Liquid biopsy 
 
• Clinically validated 
• Invasive and risky 
• Difficult to repeat 
• Failure to reflect tumor heterogeneity  
• Failure to detect metastasis at distant sites 




• Clinical practice rules are not yet established 
• Non-invasive 
• Easily repeated 
• Potential to reveal spatial and temporal tumor 
heterogeneity 
• Offers a more comprehensive picture of the 
disease 






Figure 1.1. Schematic illustration of clinical utility of liquid biopsy for lung cancer. Circulating 
biomarkers (CTCs, and ctDNA) are used for the identification of actionable mutations such as 




(ddPCR) offers promising clinical test results, which suggests the liquid biopsy based personalized 
medicine becomes a reality in near future. 
 
While CTCs have still not been validated for the use in clinical settings for the disease management 
of the patients with NSCLC, ctDNA has been approved by the Food and Drug Administration (FDA) 
in 2016 as the first liquid biopsy test for patients with NSCLC, in which the ctDNA is analyzed for the 
presence of specific mutations to identify patients eligible for treatment with the EGFR-targeted therapy. 
Herein, we provide a brief overview of the clinical perspectives and opportunities of liquid biopsy in 
lung cancer specifically focusing on the identification of actionable mutations such as sensitizing (exon 
19 and 21) and resistant (T790M) EGFR mutations, significance and uniqueness of the two most 
popular circulating biomarkers, i.e. CTCs, and ctDNA, and the detection methods of each biomarker 
and their current limitations. We further discuss the key areas of potential clinical applications of liquid 
biopsy using CTCs and ctDNA in early diagnosis, prognosis, monitoring response and resistance to 
treatment, and the remaining hurdles to overcome before the routine implementation in clinical settings.  
 
EGFR mutations and resistance mechanisms 
 
EGFR TKI drugs such as erlotinib, afatinib and gefitinib are used as the first line therapy for the 
patients with advanced NSCLCs 3-7. As schematically shown in Figure 1.1, some groups with specific 
activating mutations, deletions in exon 19 (19 Del) and substitutions in exon 21 (L858R), in the tyrosine 
kinase domain of EGFR show dramatic response to gefitinib. It is also found that a large portion of the 
responding groups are Asian women with adenocarcinoma with or without a very little previous record 
of smoking. This offers a new paradigm of personalized medicine, in which patients can predict whether 
the targeted drug would be effective for them by the mutation analysis. 
 
However, EGFR inhibitors often work only for several months or more, but eventually the drugs 
stop working because of the resistance development. One of the major resistance mechanisms is a 
secondary mutation in EGFR (T790M), which is found in 48 to 62% of EGFR TKI resistant patients. 
Recently, a third-generation EGFR TKI, osimertinib, was approved by FDA for T790M positive 
patients, which has shown significantly better efficacy than platinum-based therapy. Therefore, early 
detection of T790M mutation during the first line therapy and change the drug to osimertinib are 




Significance and uniqueness of CTCs and ctDNA as a liquid biopsy biomarker 
CTCs are the tumor cells, which are disseminated from primary tumor and/or metastatic lesions and 
circulate along the blood stream. CTCs are distinguished from other blood cells due to their positive 
expression of epithelial markers including epithelial cell adhesion molecule (EpCAM) and cytokeratins 
(CK), and negative expression of white blood cell specific marker, CD45 9. During intravasation into 
blood vessels, CTC undergoes epithelial-to-mesenchymal transition (EMT) and during extravasation 
into secondary organ, it undergoes mesenchymal-to-epithelial transition (MET). Thus, CTCs in blood 
stream have heterogeneous levels of biomarker expression related to EMT and MET 10. Heterogeneous 
CTCs can be divided into various subgroups: intact single CTCs, apoptotic CTCs and CTC clusters. 
The size range of CTC is slightly bigger than other blood cells (8 – 20 μm) but the size is also 
heterogeneous depending on the cancer type 11.  
 
As shown in Table 2, CTCs contain various cellular and subcellular components which can be used 
for further downstream analysis; e.g. intact DNA for well-known mutation analysis as well as novel 
marker discovery, RNA for gene expression profiling and various biomarkers for proteomic analysis. 
Direct visualization of cellular morphology for the identification of malignant phenotype is an important 
and unique aspect of CTCs compared to other circulating biomarkers. In addition, 
immunocytochemistry (ICC) 12 and Fluorescent in situ hybridization (FISH) 13 can be performed on 
CTCs to identify their phenotype and to detect some genomic alteration. CTCs are divided into various 
subgroups according to the cell diameter or nuclear fraction and each subgroup is analyzed for its 
characteristics 14. Isolated CTCs are cultured in vitro to establish the permanent CTC cell line for further 
studies 15-17. Furthermore, they can be applied to various in vivo, ex vivo and in vitro experiments for 
functional studies. CTC derived explants (CDXs), patient-derived xenograft models (PDXs), ex vivo 
cultured CTCs are applied to drug screening which would contribute for the personalized therapy. 
 
However, CTCs are extremely rare compared to other types of blood cells (1 – 10 CTCs/106 blood 
cells in 1 mL blood). Furthermore, CTCs are heterogeneous both in surface protein markers and physical 
characteristics. Therefore, it has been a great challenge to isolate CTCs with high sensitivity and 
specificity. For example, the CTCs isolation technologies using the anti-EpCAM antibodies cannot 
isolate the cells which undergone EMT or with low EpCAM expression. Even if 99.9% of blood cells 
are purified, the purity of the isolated CTCs is below 1%, which is at the limit of the detection of the 
currently available molecular analysis techniques. Thus, the extremely sensitive and specific isolation 
and detection methods are required to improve their clinical utility in liquid biopsy. While the 
CellSearch technology was approved for breast, colorectal, and prostate cancer by the FDA, the CTCs 




Tumor-related genetic alterations can be detected in ‘ctDNA’, which is the fragmented DNA freely 
circulating in the blood stream shed from the tumor tissue by apoptosis, necrosis and secretion of the 
tumor cells 18. The short length of DNA (~180 base pairs) is reminiscent of the ctDNA generated by 
apoptotic degradation of cellular DNA 19, 20. Due to the short length of ctDNA, the clearance is very 
rapid with the half-life of less than 2 hours 21. For ctDNA analysis, plasma samples are preferable to 
serum samples to avoid possible contamination of wild-type DNA released from other blood cells. The 
unfavorable stability of ctDNA is advantageous for real-time monitoring of the disease status though it 
adversely affects the sensitivity of the detection. Furthermore, ctDNA originates from any lesion of 
tumor in the body so that the sampling bias would be minimized. Thus, it has the advantage in the drug 
response monitoring to provide the crucial evidence whether the tumor newly developed resistance or 
not (Table 1.2). In this regard, the cobas EGFR Mutation Test v2, which is PCR-based liquid biopsy 
testing for NSCLC, has recently been FDA approved. However, the extremely low fraction of tumor-
specific genetic alterations in ‘sea’ of normal cell-free genomic DNA requires further development of 
highly sensitive, advanced molecular detection technologies as well as ct-DNA specific isolation 
methods. Recent advances in cancer management by personalized medicine has been expedited together 
with the significant progress made in ultrasensitive molecular characterization methods such as the NGS 
and third generation PCR technology (e.g. ddPCR) 22-24. 
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Table 1.2. Unique advantages and limitations of circulating biomarkers; CTCs vs ctDNA 
 CTC ctDNA 
Advantages
  






Proteomics of both cellular and sub-
cellular level 
Analysis of RNA expression 




Relevance for the metastasis 
 
Potential for full representation of 
spatial and temporal tumor 
heterogeneity 
More sensitive to tumor burden, 
treatment monitoring, and development 
of resistance 
First FDA-approved liquid biopsy test 
for NSCLC 
Relatively simple isolation method 
 
Limitations 
Extreme rarity and fragility 
Heterogeneity of CTCs 
Lack of standard isolation method 







Rarity and fragility 
Difficult to isolate tumor specific DNA 
Contamination with DNA from normal 
cells 
No functional analysis 
 
1ICC (Immunocytochemistry); 2FISH (Fluorescent in situ hybridization); 3PDX (Patient derived 





In summary, both CTC and ctDNA based liquid biopsy can contribute to cancer diagnosis, prognosis, 
and personalized treatment. EGFR mutation detection by ctDNA analysis is an exciting application of 
liquid biopsy as recently approved by the FDA. CTCs have their own advantages offering not only the 
mutation detection but also the analysis of multiple biomarkers (DNA, RNA, proteins) and 
morphological and functional analysis of intact cancer cells. Liquid biopsy using multiple kinds of 
biomarkers may minimize the sampling bias and provide more comprehensive picture of disease status. 
For example, ctDNA-based detection may be less vulnerable to the isolation methodology and better 
represent the cancer heterogeneity and longitudinal surveillance of cancer therapy while lack of 
materials and multiple choices of isolation technologies are unsolved issues for CTC analysis. On the 
other hand, the cytochemistry and morphological analysis of intact cancer cells gives valuable 
information relevant to the established cytological criteria in tissue biopsy. Furthermore, in-vivo 
functional assays using PDX model developed by CTCs can provide fundamental knowledge on the 
metastatic process and disease progression. However, both biomarkers are rare and fragile and require 
more sensitive isolation techniques from other blood components with the high-yield and high purity. 
Therefore, the improvement of the sensitivity specificity in the analysis of target biomarkers have been 
an active research area during last decades both in the chip-based rare cell isolation and advanced 
molecular characterization. Next session, we will review the representative commercialized products 
for liquid biopsy and related clinical reports on prognosis for NSCLC patients. Moreover, we introduce 
recent research papers studying molecular diagnosis based on the analysis of CTCs and ctDNA and 




1.2 Technologies for CTCs analysis and clinical applications in NSCLC 
1.2.1 Prognosis using commercially available CTCs isolation devices 
 
CellSearch (J&J, Veridex) is the only FDA approved method to enumerate CTCs, in which the 
separation mechanism is based on the isolation of CTCs using magnetic beads conjugated with EpCAM 
antibody. Though it is approved for the prognosis of patients with metastatic breast cancer (2004), 
colorectal cancer (2007), and prostate cancer (2008), it shows limited detection sensitivity for low 
EpCAM expressed CTCs. For lung cancer case, there is no validation approved yet despite many studies 
conducted to establish CTCs counts as a diagnostic and prognostic tool for NSCLC patients.  
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As shown in Table 1.3, several studies indicate that the CTC counts might be useful as a prognostic 
marker for patients with advanced lung cancer even though the detection rate was relatively low. Most 
of the studies tried to identify the baseline CTC counts as a prognostic marker and reported significantly 
poor progression free survival (PFS) or overall survival (OS) in the patient group with high CTC counts 
25-32. 
The first and representative study in NSCLC patients was reported in 2011 on the clinical meaning 
of the baseline CTC counts measured by CellSearch. Among 101 patients with advanced NSCLC (stage 
IIIA-IV), patients were divided into 2 groups according to their base line CTC counts with a cut off of 
5 CTCs / 7.5 mL. In this study, both PFS and OS were significantly poorer in CTC positive group than 
in CTC negative group (median PFS: 6.8 months vs. 2.4 months, median OS: 8.1 months vs. 4.3 months). 
Moreover, patients who had below 5 CTCs / 7.5 mL at two sequential time points achieved much longer 
PFS and OS (median PFS: 7.6 months vs. 2.4 months, median OS: 8.8 months vs. 4.3 months) 25.  
 
Other papers reported the clinical importance of not only the baseline CTC counts but also the CTC 
counts during the time course of treatment 26. Among 37 evaluable advanced NSCLC patients’ samples, 
75.7 % of patients had the positive CTC counts (≥ 1 CTCs / 7.5 mL) at baseline and they showed high 
association between baseline CTC counts and response to treatment by Response Evaluation Criteria in 
Solid Tumors (RECIST). More importantly, the change in CTC counts at 56 days after treatment had 
much stronger correlation with survival than change in CTC counts at 14 days or 28 days after treatment 
(P value at 56 days : 0.006 vs. at 14/28 days : 0.104) 26. These data suggest a correlation between the 
decreases in CTC counts upon the treatment and longer PFS, which may indicate an early response to 
the therapy.  
 
However, another study conducted with 59 advanced NSCLC patients showed that the CTC counts 
are poorly correlated with the treatment response while it was a good indicator for poor prognosis and 
the presence of distant metastasis 27. The patients with CTC counts more than the cut off value of 2 
CTCs / 7.5 mL showed significantly poor PFS and OS (median PFS: 6.2 months vs. 4.3 months, median 
OS: 11.2 months vs. 8.3 months). In addition, they noted that the CTC counts at 2 months after treatment 
were also well correlated with OS (P value of OS at baseline: 0.006 and at 2 months after: 0.008) 27.  
 
In addition, the prognostic value of the CTC subgroups was analyzed based on the characterization 
of cell morphology or the expression levels of the specific biomarkers. Among 43 patients with 
advanced NSCLC, those who had more than 5 morphologically intact CTCs showed significantly poor 
PFS and OS (median PFS: 7.6 months vs. 4.1 months, median OS: 10.7 months vs. 4.6 months) 28. 




Table 1.3. Examples of studies on CTCs-based prognosis for patients with NSCLC 




Significance* Detection rate Reference 
CellSearch 
Platinum IIIA - IV 101 5 
PFS / OS  
(P < 0.001) 14.9% 25 
EGFR TKI IIIB- IV 
37a 
(41)b 1 
PFS (P = 
0.006)** 75.7% 26 
EGFR TKI IIIA – IV 59 2 
PFS / OS  
(P = 0.01 
/P = 0.006) 
40.7% 27 
QT treatment IIIB - IV 43 5 
PFS / OS  
(P = 0.034 













DFS / OS  
(P = 0.011 






IV 208 50*** 
DFS / OS  
(P = 0.001 





IV 210 1 
DFS (P < 
0.0001) 49.5% 32 
*Progression free survival (PFS), overall survival (OS), disease free survival (DFS). P value in (27) and 
(29) are analyzed by multivariate Cox-proportional hazards regression analysis. P value in the other 
references are analyzed by Kaplan-Meier analysis. **Analyzed with CTC counts change at 56 days after 
treatment (baseline CTC: not available). ***This CTC count is not normalized with 7.5 mL. Instead, it is 
the number of CTCs from 6 mL of blood. anumber of patients whose blood sample were analyzed, 




poorer PFS. They also tested not only the intact CTCs which passed the calling criteria of the CellSearch 
system but also the CTC-like objects such as apoptotic CTCs or CK+ fragments. Interestingly, an 
apoptotic CTC positive group ( ≥ 2 apoptotic CTCs / 7.5 mL) also showed poor PFS and OS (median 
PFS: 7.6 months vs. 3.4 months, P = 0.017; median OS: 10.5 months vs. 3.6 months, P = 0.001) 28. 
 
Furthermore, a recent study with 125 patients with advanced and metastatic NSCLC showed that 
that the total CTC counts ( ≥ 5 CTCs / 7.5 mL) can be used as a prognostic biomarker for OS (HR 0.55, 
95% CI 0.33–0.92, P = 0.022) but not PFS (HR 0.68, 95% CI 0.42–1.1, P = 0.118). When they further 
analyzed the CTCs counts depending upon the Vimentin (Vim) expression and genetic subtypes (KRAS 
mutation, EGFR mutation, and ALK rearrangement), Vim expressed CTCs (≥ 1 Vim (+) CTCs) were 
significantly high in patients with EGFR-mutated cancer (total CTC (+) 57.1% vs. 30.1, P = 0.038; Vim 
expressed CTC positive 42.9% vs. 15.1%, P = 0.013), while no additional prognostic significance was 
obtained when the total CTC+ groups were subdivided into Vim(+) CTC and Vim(-) CTC groups. The 
Vim(+) CTCs were either reduced or not found in the subgroups of ALK-rearranged or KRAS-mutated 
subgroups, respectively. Because Vim is a protein marker related with the EMT, it was suggested that 
EMT characteristics can be different depending upon the genetic subtypes of NSCLC patients. However, 
the analysis has intrinsic limitation because the analysis of Vim, a mesenchymal marker, was done for 
the CTCs isolated by immunoaffinity capture using an epithelial marker, EpCAM antibody. 
Nonetheless, it suggests the importance of genetic subtypes for the clinical utility of the CTCs analysis 
29. 
 
Though majority of the CTCs analysis were conducted using the blood samples of the patients with 
advanced NSCLC, it would be certainly a ‘holy grail’ if the liquid biopsy can be used for the early 
screening of lung cancer. However, this application has not been successful yet though there have been 
a few reports worthy to note 30. For example, 30 pulmonary vein samples and 27 peripheral blood 
samples from 30 NSCLC patients not in advanced stage but in early stage (Stage I - IIIA) were collected 
to test number of CTCs by CellSearch. Much more numbers of CTCs were detected in pulmonary 
samples (43% of patients show 1 – 3093 CTCs / 7.5 mL of pulmonary sample and 22% of patients have 
1 – 4 CTCs / 7.5 mL of peripheral sample). However, the CTC counts from pulmonary sample had no 
significant correlation with the survival. Only the CTC counts from peripheral sample were strongly 
related with poor disease free survival (DFS) and OS (P = 0.011 and P = 0.037) 30. 
 
To overcome the limitation of EpCAM-based isolation methods, separation techniques based on the 
differences in physical properties are also developed. For example, ISET (Rarecells) uses size 
difference between CTCs (8 ~ 20 μm) and other blood cells (6 ~ 10 μm). Compared to immunoaffinity-
based methods, the size-based filtration is relatively simple and fast. Though the cell sizes are 
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heterogeneous as well, the number of CTCs isolated by using a track-etched polycarbonate membrane 
with pore diameter of 10 μm were higher than that of CellSearch methods 31, 32. For example, the CTC 
positive group with the cut-off value of 50 CTCs/6mL, 30.8 % of 208 patients with NSCLC, had 
significantly poorer PFS and OS than the CTC negative group (P = 0.002 and 0.001, 31). In a follow-up 
paper, 50% of patients had positive CTC detection with high correlation with DFS (P < 0.0001) when 
they used the cutoff value of 1 CTC / 7.5 mL. Interestingly, the patients who had positive CTC detection 
in both CellSearch and ISET had a stronger correlation with poor survival than patients who had positive 
CTC detection from only one method 32. 
 
Taken together, the clinical meaning of CTCs counts still remains controversial although many 
studies indicate that the high CTCs count has strong correlation with poor survival. The number of 
CTCs is highly variable depending on the tumor types, patients groups, and the methods used for the 
isolation. It would require further validation to answer whether the CTC counts can be used for the 
prediction of the therapy response. The additional characterization of CTCs using molecular or protein 
markers are required to improve the clinical impact of CTCs. These limitations will be overcome by the 
development of more robust technologies with improved assay performance. Many new microfluidic 
chips based rare cell isolation technologies achieved higher yield and purity compared to the currently 
commercially available devices even though larger scale clinical tests with various patient groups are 
required before the validation of CTCs as a prognostic marker in clinical studies. 
 
1.2.2 Molecular diagnosis using isolate CTC by microfluidic chips  
 
In order to use CTCs for molecular diagnosis, the purity should be higher than the minimum 
requirements of the downstream molecular analysis techniques such as PCR and NGS. Therefore, many 
devices have been developed to improve the capture efficiency and purity. Here, we will review the 
most recent devices that have been used for the molecular analysis of CTCs isolated from patients with 
NSCLC as summarized in Table 1.4. 
In order to improve the capture efficiency, HbCTC-Chip which has herringbone pattern on the 
channel roof was developed (Figure 1.2a). The contact frequency between CTCs and EpCAM antibody 
coated on the chip surface could be highly enhanced by the microvortex formed due to its herringbone 
pattern. HbCTC-Chip achieved higher capture efficiency than flat channel in PC3, a prostate cancer cell 
line, spiked experiment (Capture efficiency of HbCTC-Chip: 79% ± 4.5% and Flat chip: 29% ± 4.3%). 









Table 1.4. Summary of reports on mutation detection in CTCs from patients with NSCLC. 
Isolation 
















sequencing T790M 50 % (14/28) 
57% 
(12/21) 
Nanovelcro36 EGFR TKI III - IV 7 Sanger sequencing 
L858R / 
T790M 
85.7 % (6/7) 




retrieval37 EGFR TKI IV 






16.7 % (1/6) 
66.7 % (4/6) 
100 % 
(6/6) 
MagSifter39 NA I-IV 7
 a  
(35) b RT-PCR 
19 del / 
L858R / 
T790M 
42.9 % (3/7) 
14.3 % (1/7) 
42.9 % (3/7) 
NA 
OncoBean 
Chip41 NA I-IV 
4 a  
(36) b RT-PCR 
EGFR / 
KRAS 
25.0 % (1/4) 
50.0 % (2/4) NA 
aNumber of patients whose CTCs were isolated and used for genotyping; bnumber of patients who 
enrolled in the study. Nanovelcro and Single cell retrieval required at least 3 repeated processes.  
* Capture efficiency of MagSifter >95%, release efficiency 92.7 ± 6.1%, cells collected in eluted 
fraction 89.6 ± 12.1%; ** Purity was measured by spiked experiment except MagSifter (clinical sample 








Figure 1.2. Examples of CTC isolation chips used for the mutation analysis of CTCs from patients with 
NSCLC. (a) HbCTC-Chip, which has a herringbone pattern on the channel roof, was developed to 
improve capture efficiency (Right : 1”  3” glass slide)33,34; (b) The purity of the cells captured by 
NanoVelcro chip, which has silicon nanowires on its bottom substrate to maximize the surface bound 
antibody, were further improved by thermoresponsive purification step36; (c) A microfluidic device (3.5 
cm  2.5 cm PDMS chip) capable of single-cell isolation and retrieval was developed to improve 
purity37; (d) A nanowell array filled with CTCs magnetically captured by a dense array of magnetic 
pores (MagSifter) were used for multigene expression profiling from individual CTCs (Upper scale bar: 
200 μm, lower scale bar: 50 μm)38,39; (e) OncoBean Chip, which has bean-shaped posts coated with 
antibodies were developed to improve the throughput (Right: 2”  3” glass slide)40,41. Reproduced 
from ref. (33–41) with permission from the United States National Academy of Sciences, American 
States National Academy of Sciences, American Chemical Society, Nature Publishing Group, Royal 





(14/15 patients) 33. In addition, HbCTC-Chip was further utilized to detect T790M mutation in the EGFR 
mutant NSCLC patients to monitor the development of resistance to EGFR TKI therapy. From 40 
patients with advanced NSCLC, genotyping was possible in 28 CTC samples (70%) and T790M could 
be detected from 14 (50%) patients, which was in 57% concordance with primary tissue biopsy result 
34. 
 
Another representative device in immunoaffinity based CTC isolation is ‘NanoVelcro’ which has 
silicon nanowires on the bottom substrate offering significantly enhanced surface area to contain larger 
amount of EpCAM antibody and micropattern on the roof for chaotic mixing to promote efficient 
mixing. In the performance comparison with CellSearch, NanoVelcro obtained much higher detection 
rate with 26 patients with prostate cancer; the detection rate of NanoVelcro was 76.9 % (20/26 patients) 
while CellSearch results were 30.8% (8/26) 35. A follow-up study using additional thermoresponsive 
purification step reported a significantly improved purity from 35% to 98% when the tests were 
performed with blood samples spiked with H1975 NSCLC cell line (Figure 1.2b). From 7 advanced 
NSCLC patients, they could achieve 100% concordance in the detection of the EGFR L858R mutation 
from CTCs and tissue biopsy samples. Especially, two patients had EGFR T790M mutation in the 
relapse tissue samples and it was also detected in patient-derived CTC samples 36. 
 
In order to improve the purity, a microfluidic device capable of single cell isolation and retrieval 
was developed. The cells are first hydrodynamically focused in a single stream in the main fluidic 
channel, and then guided into the single cell capture chamber due to the intrinsic pressure difference 
(Figure 1.2c). The trapped single CTC can be released on-demand to the main channel by positive 
pressure. The rare CTCs could be isolated with 100 % purity. This microfluidic single cell capture 
device was applied to detect EGFR L858R and T790M mutation from patient-derived CTCs by Sanger 
sequencing. A total of 26 CTCs were isolated from 6 of 7 patients, which is in 100% concordance with 
the corresponding tissue biopsy samples 37. 
 
Furthermore, multigene expression profile from individual CTCs could be performed on a Nanowell 
array filled with CTCs magnetically captured by a dense array of magnetic pores, MagSifter 38. The 
nanowell array can capture CTCs up to 25,600 cells and single cell level multigene RT-PCR could be 
performed for molecular characterization of single CTCs (Figure 1.2d). CTCs, defined as EpCAM+ 
cells with expression of both TERT and MET in a nanowell, were found in 31 of 35 (88.6%) patients 
with the cut-off of 7 CTCs in 2 mL. They also confirmed EGFR 19 del, L858R, and T790M mutations 




In order to improve the throughput, OncoBean Chip which has bean-shaped posts coated with 
combination of multiple antibodies such as EpCAM, EGFR, and CD133 with a radial flow enabling 
increased cell capture under high flow rate conditions was developed (Figure 1.2e). Based on cell line 
spiked experiment, the OncoBean Chip achieved more than 80% of capture efficiency at 10 mL/hr flow 
rate 40. CTCs were detected in 69.4 % and 83.3% of total 36 patients with NSCLC from intraoperative 
peripheral (Pe) and pulmonary vein (PV) blood samples, respectively. In this study, pulmonary vein 
cases achieved much higher CTC counts (0 – 10,278 per 3 mL, with a median of 7.5 CTCs per 3 mL), 
than peripheral vein cases (0 – 28.5 per 3 mL, with a median of 1.3 CTCs per 3 mL) 41. In addition, 
CTC clusters were found in 50% of patients and interestingly, clusters found from PV were larger. 
Considering the fact that the CTCs found in PV are before going through the systemic circulation, it 
could be assumed that PV is an enriched source of CTCs with larger sized clusters. On the other hand, 
CTC clusters were either not found in Pe or smaller in size, which suggests that bigger clusters may not 
able to enter the systemic circulation or dissociated in the areas of smaller vasculature. It was found that 
the presence of the clusters in preoperative Pe was an indicative of poor prognosis. Furthermore, the 
mutations were found in 5 of 6 samples tested involving at least one of the genes CTNNB1, EGFR, 
KRAS, PIK3CA, and TP53. It is noteworthy that the gene expression analysis of CTCs recovered from 
PV and Pe were different, e.g. TP53 expression was higher in CTCs from Pe while ERCC1 was higher 
in PV samples, which may suggests the molecular heterogeneity of CTCs from two different sources. 
 
In summary, there are evidences that the isolated CTCs can be used as a biomarker to determine 
poor prognosis and to predict recurrence. In order to improve the sensitivity and specificity as a 
biomarker for cancer management, various microfluidic chips are developed and used for molecular 
diagnostics for the selection of personalized medicine. Currently, rather limited numbers of studies were 
conducted for patients with NSCLC due to the rareness of CTCs in lung cancer, however, the results 
are promising and it is expected to have more advanced technologies because the mutation detection in 
subgroups of NSCLC patients is directly linked to the choice of actionable drugs and personalized 
cancer management. 
1.3 Research motivations 
For past few decades, liquid biopsy has been considered as the noninvasive alternative to tissue 
biopsy. Liquid biopsy is gaining enormous interest among clinics as it provides specific information to 
help doctors for decision of a proper treatment to patients at various stages of their disease. For this, 
several devices were developed for CTC isolation and validated clinical utility of CTCs as diagnostic, 
prognostic and treatment monitoring markers in cancer patients. Simultaneously, various methods of 
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molecular analysis such as sequencing or mutation analysis were also developed to study and 
understand their clinical implications. 
 
Although many studies have demonstrated reliability of the liquid biopsy using CTC, until now 
there is no consensus on the criteria of CTCs as the prognostic markers in NSCLC due to the limitations 
such as lack of congruence; difficulties in standardization of the sample preparation and isolation 
method as well as selection of the sample type; heterogeneity of the samples; variations in marker 
expression such as EMT underwent CTCs with the lack of epithelial marker expression; reproducibility; 
selectivity and sensitivity etc. Furthermore, the selection of the blood collection tubes, blood volume, 
and type of downstream analysis, could affect the quality of the data and may induce inaccuracies and 
statistical errors. Related with the validation of liquid biopsy, Torga et al. recently report that 
independent tests at two different laboratories with identical sample showed only 7.5% of cases with 
completely matched mutations. This study emphasizes the necessity of standardization based on the 
development of the robust system and the importance of the prior validation of each technique with 
multicenter large-scale study for the real application of liquid biopsy in clinical routine. In addition, 
standardized protocols for blood collection and sampling are also accompanied to minimize the 
technical errors 42.  
 
The above discussion clearly rationalizes that the development of a robust device for CTC isolation 
is necessary and analysis of isolated CTCs at single-cell level is essential to better understanding of 
cancer heterogeneity. Through this thesis, robust centrifugal microfluidic device will be demonstrated 
utilizing the new technique to prevent clogging issue. We expect this thesis can suggest the expansion 




1.4 Research aims 
 
The research aim in this thesis is the development of robust device for CTC isolation and single 
cell analysis with isolated CTCs to find clinical meaning. Here, we demonstrate a clog-free CTC 
isolation device in label-free manner and mRNA profiling based CTC characterization.  
 
Development of clog-free CTC isolation disc in label-free manner 
In this thesis, the fast, simple and user friendly device for CTC enrichment with high performance 
was demonstrated. To take the advantages of lab-on-a-disc system and fluid-assisted separation 
technology(FAST), we developed the label-free and clog-free FAST disc. The FAST disc has high 
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capture efficiency regardless of the expression level of cell surface markers. The performance of disc 
was confirmed across the 142 cancer patients with 7 different cancer types including lung cancer, breast 
cancer, and pancreatic cancer. Moreover, the high robustness of the disc was confirmed with 
repeatability test during the 30 days. It is expected that this novel platform will possibly contribute 
toward liquid biopsy applications by providing a robust and practical solution for clinical field.  
 
Single cell analysis of isolated CTCs to find clinical meaning 
In second, clinical meaning of isolated CTCs related to prognosis was demonstrated. We confirmed 
the relationship of CTC counts and stage, survival, and drug response in NSCLC. We also compared 
the EGFR mutation which detected from CTCs and tumor tissues and achieved 100% concordance in 
13 lung cancer patients. Moreover, T790M mutation, which related with the resistance about EGFR-
TKI, is detected in two patients who had T790M mutation in tumor tissue from 2nd tissue biopsy result. 
We analyzed the gene expression profiling with patient-driven CTCs in single cell level and found 




CHAPTER 2. Development of clog-free CTC isolation disc in label-free 
manner 
 
2.1 Centrifugal microfluidics for size-based CTC isolation  
2.1.1 Centrifugal microfluidics 
In microfluidics field, lab-on-a-chip has been studied by many researchers in order to miniaturize 
and integrate several laboratory functions on microfluidic platforms 43-45. One of the final goals is to 
develop a lab-on-a-chip in which all of the required analytical procedures are carried out on single chip. 
The user would simply add sample; then the chip would automatically process sequential steps of the 
assay and return the results. However, lab-on-a-chip requires multiplex operating system, including 
many pumps connected with several tubings, in contrast with the simple and small construction of the 
chip 46, 47 (Figure 2.1a,b). To overcome the limitation, centrifugal microfluidic platform, also known as 
lab-on-a-disc, have emerged with simple operating system which composed with a rotor 48 (Figure 2.1c). 
It uses centrifugal force as driving force and makes possible to perform various manipulations including 
valving, metering, mixing and pumping of reagents so it can be applied to point-of-care clinical 
diagnostics. 
 
In centrifugal microfluidics, there are three intrinsic forces (Figure 2.1d) on a spinning system 
including centrifugal force (Fc), Coriolis force (Fco), and Euler force (FE) 49. These forces are 




In the equations, m is the mass of point-like body where the forces exerted at position r from the center 
of the spinning system and ω is the angular velocity. Fc exerts radially outward, while the Fco force acts 
perpendicular to both of the fluid velocity and the angular velocity in the spinning system. Lastly, the 
FE acts proportionally with angular velocity. 
 
Because the spinning of a disc induces fluid transter, operating system of lab-on-a-disc, including a 







Figure 2.1. Microfluidic systems, lab-on-a-chip and lab-on-a-disc. (a) Image of miniaturized lab-
on-a-chip 46. (b) Image of operating system of lab-on-a-chip 47. (c) Scheme of lab-on-a-disc and 
operation system 48. (d) Forces acting in a spinning system 49. 
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2.1.2 Membrane filtration  
Size based CTC isolation has strengths related with fast and simple operation in unbiased isolation 
of CTCs compared to immune-affinity based CTC enrichment. Membrane filtration, one of the size 
based CTC isolation, is used a porous membrane, which pore size is range of 5 – 8 μm, to isolate CTCs 
from other blood cells 11. The most critical problem of membrane filtration is clogging issue due to the 
billions of blood cells, RBCs and WBCs. Because the flow direction of fluid is perpendicular to the 
membrane surface, the retained cells are collected on the membrane surface forming a filtration cake 
and occur clogging issue. Moreover, cake layer can increase the pressure drop which induces the 
damage to cells 50 (Figure 2.2a).  
 
To prevent clogging issue induced by cake layer, pretreatment of blood, such as blood dilution or 
RBC lysis, is applied to reduce the concentration of cells for increasing the efficiency of filtration 51. 
However, each pretreatment has drawbacks; longer process is induced by blood dilution due to the 
increase in total volume of blood sample and RBC lysis can reduce the capture efficiency of intact CTCs 
because lysis buffer can affect to not only RBCs but also CTCs. The other case of membrane filtration, 
tangential-flow filtration, can be a good solution to prevent clogging issue. In tangential-flow filtration, 
the direction of feed flow is tangential to the membrane surface while the transferred permeate flow is 
perpendicular to the other side of the membrane 50 (Figure 2.2b). Due to its perpendicular feed direction 
to the membrane, it prevents increases higher permeate rate and lower flux decline according to the 
decrease of the cell accumulation on the membrane surface. 
 
To take the advantage of tangential-flow filtration, porous membrane is inserted into the lab-on-a-
disc parallel to the direction of flow which induced by centrifugal force (Figure 2.2c).    
 
Although tangential-flow filtration enhances the filtration efficiency, high fluid velocity was 
required to limit the growth of cake layer on the membrane accompanying the high energy and large 










Figure 2.2. Scheme of membrane filtration. (a) Dead-end filtration (normal flow filtration) with cake 
layer. (b) Tangential-flow filtration (cross-flow filtration). (c) Insertion of memrane into the lab-on-a-
disc for taking the advantage of tangential-flow filtration.  
22 
  
2.2 Fluid assisted separation technology (FAST) disc for CTC enrichment 
2.2.1 Introduction 
Circulating tumor cells (CTCs) shed into the peripheral blood from primary and metastatic tumors 
are important biomarkers for early detection of invasive cancer as well as for treatment monitoring in 
personalized cancer therapy.52, 53 Since CTCs exist in extremely low concentrations (only a few CTCs 
out of a billion normal blood cells), the enrichment of CTCs with high recovery and purity has been a 
great challenge. Furthermore, CTCs are very fragile and thus it is highly recommended to do analysis 
within 6~8 hours after the blood collection from patients. Therefore, there is strong needs to develop 
rapid, efficient, robust, and affordable point-of-care CTC isolation technologies that could be broadly 
deployed in clinical settings.54, 55 
 
Among previous efforts to selectively enrich CTCs from peripheral blood, the most common 
immunoaffinity-based capture strategy provides relatively high sensitivity and specificity, but the 
process time is long (> 1~4 hours).9, 56 As a complementary method, the separation technologies based 
on the differences in physical properties such as size,57-67 density,68, 69 deformability,70 and electrical 
properties71-73 were also developed. Even though each strategy has its own advantages and limitations56, 
74-76, size-based isolation methods utilizing various2kinds of microfilter structures offer high throughput 
as well as simple protocols facilitating automation and commercialization.77-79 
 
Existing technologies for size-based isolation of CTCs have strived to improve the recovery rate 
and purity by developing expensive lithography-based microfilters with regular pore sizes and shapes.59-
61 Preferably, blood samples should have a prior dilution 61, 62 and/or fixation79 and optimum 
transmembrane pressure should be maintained in order to achieve higher recovery rate and to avoid 
frequent clogging.60, 67 Commercially available track-etched polycarbonate membranes are also utilized 
for CTC capture. Although this approach has some merits in terms of cost and mass production, it can 
attain only lower-than-desired recoveries with poor purity due to non-uniform and randomly distributed 
pores and low porosity.60, 65-67  
 
We previously developed a lab-on-a-disc platform which allows rapid size-based isolation of CTCs 
with relatively high purity starting from whole blood.66 Based on these advantages, we herein report  
* Chapter 2.2 is reproduced with the permission from “T.-H. Kim‡, M. Lim‡, J. Park‡, J.M. Oh‡, H. Kim; H. Jeong; 
S.J. Lee; H.C. Park; S. Jung; B.C. Kim; K. Lee; M.-H. Kim; D.Y. Park; G.H. Kim; and Y.-K. Cho, Analytical 








Figure 2.3. Design and function of the FAST disc. (a) Schematic illustration showing the mechanism 
of the Fluid-Assisted Separation Technology (FAST) disc. The pressure required to force a blood sample 
(red) through a membrane with liquid-filled pores (FAST) is expected to be much lower than that 
required to achieve transport through a bare membrane (non-FAST). The filtration occurs mainly in the 
outer rim of the filter with a disc spinning in non-FAST mode, whereas a more uniform transport of 
liquid takes place with the FAST disc, as demonstrated in the images showing 10 μm red fluorescent 
beads filtered with the conventional (top) and FAST (bottom) methods. (Scale bar: 100 μm) (b) Images 
of lab-on-a-disc and portable operation system. The track-etched polycarbonate membrane with 8 μm 




a dramatic increase in recovery rate (from 54.0 ± 21.0% to 95.9 ± 3.1%) by utilizing the same track- 
etched polycarbonate membrane with 8 μm pores and unprocessed pheripheral blood but with a fluid-
assisted separation technology (FAST), termed “FAST disc”, for which size-selective CTC isolation is 
performed through the membrane pores filled with a stably-held liquid during the entire filtration 
process (Figure 2.3a). As we show, the FAST disc approach enables a stand-alone, efficient, user-
friendly, robust and cost-effective lab-on-a-disc system for point-of-care isolation of CTCs. We 
demonstrate its applicability to CTC capture and downstream molecular analysis with samples from 
patients with various types of cancer. 
 
2.2.2 Experimental details 
Disc fabrication process. The disc was designed with a 3D CAD program and milled with a CNC 
milling machine (3D modeling machine; M & I CNC Lab, Pyeongtaek, Korea). Polycarbonate sheets 
(PC: I-Components Co., Ltd, Pyeongtaek, Korea) were used for the body, which was milled from 
several layers. After milling, all of the layers were laminated using a pressure-sensitive double-sided 
adhesive (DFM 200 clear 150 POLY H-9V-95, FLEXcon, Spencer, MA). To form an easily detachable 
membrane, a supporting back plate equipped with a membrane holder and a gasket was assembled on 
the bottom of the disc body.  
 
Samples. MCF-7, MDA-MB-231, MDA-MB-436 breast cancer cell lines, HCC78 lung cancer cell 
lines, and the AGS gastric cell line were purchased from ATCC (Manassas, VA). All of the cells were 
cultured in RPMI medium supplemented with 5% FBS and 1% antibiotics/antimycotics in incubators 
set to 37°C, under a 5% CO2 atmosphere. For the spiking experiments, the cells were pre-labeled with 
a fluorescent dye CellTracker CMTMR (Life Technologies, Carlsbad, CA) according to the 
manufacturer’s recommended protocol. 
 
Blood samples. For blood sample preparation, peripheral blood samples from patients were 
obtained from the Pusan National University Hospital (Busan, Korea). This study was reviewed and 
approved by the Institutional Review Board (IRB) of PNUH and UNIST. Blood was collected in a K2-
EDTA tube and inverted 10 times, immediately after the drawing of the blood. The blood samples were 
tested within 8 h of being collected to prevent cell damage. In the FAST disc experiments, the whole 
blood was used as is without dilution or red blood cell (RBC) lysis. 
 
Isolation of CTCs from whole blood. Before the isolation of the CTCs, the surface of the disc was 
passivated with BSA. A 1% BSA solution was injected into the disc and then incubated for 30 min. The 
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BSA solution was then removed to the waste chamber by rotating the disc, after which the surface was 
washed with 1 mL of PBS solution. After the surface passivation, 3 mL of whole blood was introduced 
to the disc without any sample pretreatment steps. The CTCs were isolated on the filter by spinning the 
disc and then the filter was washed two times with 1 mL of PBS solution. The total filtration time 
required to isolate CTCs from 3 mL of whole blood was less than 1 min. To count the captured CTCs 
on the filter, immunostaining process was conducted on a disc. 
 
Immunostaining process. The CTC isolation steps were followed by an immunostaining process 
to identify the cancer cells. The immunostaining process was also performed on the disc. First, the 
captured cells on the filter were fixed with 4% formaldehyde for 20 min at room temperature and then 
washed with PBS buffer. All of the pumping needed to generate the flow during the staining process 
was induced by the rotation of the disc at 600 RPM for 6 s. The fixed cells were permeabilized with 
0.1% Triton X-100 in PBS for 5 min and then washed with PBS. After the permeabilization of the cells, 
the blocking step with 20 μg/mL of IgG was followed by staining with several antibodies. To stain the 
white blood cells, an anti-CD45 solution (H130, Life Technologies, Carlsbad, CA) was injected, 
incubated for 20 min, and then washed with 0.01% Tween 20 in PBS. Next, the CTCs were stained with 
a mixture of anti-cytokeratin conjugated FITC (CAM5.2, BD, San Jose, CA), anti-pan-cytokeratin 
conjugated Alexa 488 (AE1/AE3, eBioscience, San Diego, CA), and anti-EpCAM conjugated FITC 
(9C4, BioLegend, San Diego, CA). A mixture of these antibodies was introduced to the filter, incubated 
for 20 min, and then washed with 0.01% Tween 20 in PBS. Finally, the nuclei in the cells were stained 
with DAPI. Fluorescent images to confirm the CTCs were taken by using IX71 fluorescence 
microscopy (Olympus, Tokyo Japan) under 40× magnification. The captured cells were identified as 
CTCs if they exhibited the characteristic immunostaining feature of CK+ or EpCAM+, CD45- , DAPI+, 
and their diameter was in excess of 8 μm. The cells exhibiting EpCAM- and CK-, CD45+, and DAPI+ 
were identified as WBCs. Cells exhibiting EpCAM+ or CK+, CD45+, and DAPI+ were also found in 
several clinical samples (not in the healthy donor’s blood) and they were defined as atypical cells.  
 
Pressure drop measurement. A pressure sensor (MP3V5004DP, NXP Semiconductors, Eindhoven, 
Netherlands) with a measurement range of 0–3.92 kPa was employed with a data acquisition board 
(Arduino Pro Micro, Shenzhen Wonderwing Electronics Ltd., Shenzhen, China) combined with a 
Bluetooth module (HC-06 V1.4, Guangzhou HC Information Technology Co., Ltd., Guangzhou, China) 
in order to measure the pressure drop through the membrane during the spinning process. The pressure 
sensor, data acquisition board, Bluetooth module, and button cells were all integrated onto a disc and 
assembled onto a FAST disc for CTC isolation. The Coolterm software was utilized to acquire the data 
during the rotation. 
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Numerical simulations. The numerical simulation was performed by using open source code, 
OpenFOAM1. The domain of interest (DOI) was simplified into a membrane with a uniform pore size 
and distribution. The pore size and membrane thickness were set to 80 m and 100 m, respectively. 
The reservoir chamber was also simplified to reduce the computation cost. The generated mesh has 
5,597,401 cells with 17,669,111 faces. The multiphase flow problem including blood, water, and air 
phases is discretized based on the volume of fluid with the continuous surface force (VOF-CSF) method. 
The two-equation eddy-viscosity model with the shear stress transport formulation (k- -SST 
turbulence model) was used to compensate for abrupt pressure fluctuations during high-speed spinning. 
The DOI rotates at 600 rpm, which is implemented by the moving reference frame (MRF) option in 
OpenFOAM. Its angular velocity increases linearly from t = 0–0.02 s, after which it is held constant 
until the end of the simulation time ( ). The loading and filtration chambers were initially 
filled with the blood phase while the lower priming chamber was filled with air for the non-FAST case, 
and with water for the FAST case, respectively. All of the physical properties including the density, 
viscosity, and surface tension were set as constants at room temperature. All of the numerical 
visualizations were implemented in the Paraview open source software. 
 
Flow rate calculation. The flow rate was calculated using the hydrodynamic resistance model 




where  and , . Here,  is the fluid 
viscosity, and , and  are the pore diameter, thickness, and porosity of the membrane, respectively. 
The number of pores ( ) is determined by  and the membrane area. 
 
Electric circuit equivalent model. The concept of a hydrodynamic resistance model can be 
extended to a general situation. Microfluidic networks are known to exhibit similarities to electric 
circuit networks. If we liken the flow rate and pressure difference in microfluidics to the electric current 
and potential difference in electric circuits, the microfluidic flow networks can be represented in terms 
of resistance, capacitance, inductance, etc., in the so-called electric circuit equivalent model. Figure 
2.9a and Figure 2.9b show simplified schematics of the non-FAST and FAST modes together with 
corresponding electric circuit equivalent models. Here,  and  represent the pressure, 
flow rate, flow resistance, inductance, and capacitance, respectively.   and   for microfluidic 
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channels are well known and are described well in Oh et al.3. The capacitance  can be modeled as 











where  and  . Further,  is the initial pressure of  ;  converges to 
. The convergence time depends on the inductance ( ) of the outlet channel, while the 
characteristic time scale is s in this case, which is much shorter than for the non-FAST 
case. The response in the FAST case is spontaneous and has no underdamped oscillation. This means 
that the FAST method is much more stable than the non-FAST method. For the non-FAST case, the 





The stability of the non-FAST case is highly dependent on the outlet resistance as well as the membrane 
resistance, as shown in Figure 2.9c and Figure 2.9d. If there is an air phase in the waste chamber (e.g. 
in the non-FAST case), the flow rate can fluctuate unexpectedly, and backflow is even possible 
according to the outlet channel size. To enable the conservative design of microfluidic configurations, 
the microfluidic channel dimensions should also be optimized considering both cases. 
Evaluation of capture efficiency. To confirm the capture efficiency and WBC depletion ratio of 
the FAST disc, 1 μL of cell suspension with a concentration ranging from 1–100 cell/μL was pre-
counted and directly spiked into 1 mL of healthy donor’s blood. In this case, the MCF-7 cells were used 
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after staining with CellTracker™ Green CMFDA dyes. After filtration, the membrane was released from 
the FAST disc and mounted on a slide glass with a DAPI mounting solution. The entire membrane was 
scanned and imaged with a fluorescence microscope, after which the CellTracker+/DAPI+ cells were 
counted to determine the capture efficiency, which was defined as the captured number of cells divided 
by the input number of cells (%). 
 
Culture process for captured cancer cells. After isolating the cancer cells using the FAST disc, 
the membrane was released from the disc without performing the staining process and then introduced 
to the culture plate. The RPMI medium, supplemented with 5% FBS and 1% antibiotics/antimycotics, 
was added to re-suspend cells from the membrane surface. Then, the membrane was removed from the 
culture plate and the cells were incubated at 37°C in a 5% CO2 atmosphere. To remove the remaining 
white blood cells, the RPMI medium was changed every other day. After 15 days, a live/dead assay 
(Life Technologies, Carlsbad, CA) was performed by following the manufacturer’s recommended 
protocol. 
 
Performance comparison with ScreenCell. To test the CTC isolation performance of the FAST 
disc, we divided the blood samples into two aliquots (~3 mL each) and tested them with the FAST disc 
and ScreenCell (Sarcelles, France), a commercially available size-based isolation kit, respectively. In 
the ScreenCell experiments, the manufacturer-recommended protocol was adopted. In summary, the 
FC2 buffer (pH 6.7, 4 mL), composed of an RBC lysis and fixation buffer, was mixed with 3 mL of 
whole blood. After being incubated for 7 min, the pretreated blood sample was introduced into the 
loading chamber. Blood filtration occurs as a result of the negative pressure produced by plugging the 
vacuum tube. After filtration, 1.4 mL of PBS buffer was introduced for washing. Finally, the system 
was disassembled to separate the membrane, followed by immunostaining and counting. 
 
DNA isolation and detection of KRAS and EGFR mutation. To detect the mutation of isolated 
CTCs, DNA extraction from the H358, PC9 lung cancer cell lines, as well as from blood samples taken 
from patients with lung cancer was performed using an Amoy DNA prep kit (AmoyDx, Xiamen, China). 
The KRAS and EGFR mutations of gDNA was performed using an Amoy mutation kit based on real-
time PCR, which has received the approval of the State Food and Drug Administration (SFDA) for 
clinical usage in mainland China. The EGFR mutation kit covers the 29 EGFR mutation hotspots from 
exon 18 to 21. The assay was carried out according to the manufacturer’s protocol with a real-time PCR 
system (ViiA7, Life Technologies, Carlsbad, CA). A positive or negative result was obtained if it 




2.2.3 Result and discussion 
Design and function of the FAST disc. The rationale used to design the FAST disc was that 
membranes with liquid-filled pores can provide a reduced pressure drop for size-selective filtration80 
and thereby gentler yet more efficient filtration could be achieved (Figure 2.3a). In the case of 
conventional filtration, the transport of liquid occurs at a specific pressure that is higher than a critical 
value affected by interaction with solid surfaces, the pore size and geometry, and the surface tension. 
The wetting behavior and meniscus formation tends to be non-homogeneous through the membrane 
and the system is prone to fouling. With a FAST disc, however, the pores are primed with liquid stored 
in the fluid assistant chamber positioned underneath the membrane and the complete wetting remains 
during the entire filtration process, such that the liquid flow requires a minimal pressure difference and 
filtration occurs more uniformly throughout the entire membrane. 
 
To realize a robust and user-friendly CTCs’ isolation platform that can be readily adapted to clinical 
settings, we have developed a custom-designed portable spinning machine (Figure 2.3b). The FAST 
disc has a microfluidic layout composed of three independent filtration units; each unit consists of three 
chambers for sample loading, filtration, and waste storage. The membrane is detachable so that it can 
be easily mounted on a slide glass for follow-up image analysis and molecular characterization (Figure 
2.4). In a centrifugal microfluidic device, the liquid is pumped radially outwards as the disc spins.66, 81 
Whole blood sample injected into the sample loading chamber is gently pushed into the filtration 
chamber and larger epithelial CTCs are captured by the membrane while smaller hematopoietic cells 
pass the membrane to be transferred to the waste chamber. The operation procedure is very simple; 
sequentially adding whole blood, washing buffer, and staining reagents is followed by pushing a button 
on the LCD panel of the custom-designed instrument which spins the disc (Figure 2.5). 
 
The dramatic difference between FAST and non-FAST mode operation was first highlighted with 
filtration experiments using fluorescent particles measuring 10 μm in diameter (Figure 2.3a and Figure 
2.6). In non-FAST mode filtration on the spinning disc, the majority of the particles are located in the 
outer rim of the filter, suggesting that only small portions of the membranes are actually used for the 
filtration, whereas a more uniform distribution of particles was observed in FAST mode. This is 
achieved by simply having priming water under the membrane such that the membrane is fully wet 
before and during the entire filtration process. This makes sure that the liquid transport occurs at a 







Figure 2.4. Expanded view of the FAST disc. A FAST disc is composed of 4 polycarbonate plates 
and 3 layers of pressure sensitive adhesive (PSA) tape sandwiched between the plates. The track-etched 
membrane is then assembled with detachable parts including o-rings, gaskets, holders, and a back plate 










Figure 2.5. Images showing the experimental procedure for CTC isolation from whole blood using 
the FAST disc system. (a) 3 mL of whole blood was injected into the FAST disc without any prior 
sample treatment. (b) The disc was loaded into the custom-designed operation machine and (c) filtration 
was conducted by spinning the disc according to the preloaded spin program. (d) After CTC capture 














Figure 2.6. Distribution of the particles on the membrane after filtration. A suspension of 
fluorescent polystyrene particles with a diameter of 10 μm was filtered by spinning the disc at 600 rpm 
in conventional (non-FAST) and FAST mode. (a) The particle distribution was analyzed as a function 
of the radial position. (b) Image analysis shows that only part of the total area is used for filtration in 




The key advantages of the FAST disc, i.e., faster filtration and a reduced pressure drop, are further 
confirmed by means of whole-blood separation. The pressure drop measured by a wireless pressure-
sensor system installed on the spinning disc (Figure 2.7a) showed a 50% reduction in the pressure drop 
for the FAST disc (Figure 2.7b). As shown in Figure 2.7c, it takes less than 20 s to filter 3 mL of whole 
blood using a FAST disc while about 100 s is necessary for non-FAST mode filtration. Compared to 
our previous report on CTC isolation using a non-FAST disc66, the capture efficiency was greatly 
enhanced from 54.0 ± 21.0% to 95.9 ± 3.1% with the use of the FAST disc (Figure 2.7d). Taken together, 
it was validated that the FAST disc realizes faster filtration with high recovery despite there being a 
smaller pressure difference, which should be ideal for the size-selective filtration of live cells. 
 
Simulation and theoretical analysis of FAST.  
 
The flow field during the filtration process analyzed by means of numerical simulation also supports 
our argument from a fluid dynamics point of view. The volume of fluid method with continuous surface 
force is used to simulate multiphase flows in a complicated geometry.  
 
With the rotation of the disc, the blood phase is pushed into the upper filtration chamber by 
centrifugal force, where it accumulates until the pressure difference between the upper and lower sides 
of the membrane reaches a threshold value which overcomes the capillary resistance in the non-FAST 
case (Figure 2.8a). The hydrodynamic pressure does not change much in the lower priming chamber 
and it induces a non-uniform pressure drop across the membrane surface, as shown in Figure 2.8b and 
Figure 2.8c. As a result, the blood phase mainly flows only through a small portion of the frontal area 
of the membrane, which significantly reduces the efficiency of the filtration. The filtered blood phase 
is not accumulated in the lower chamber but rather drains to the outlet immediately, which makes this 
inefficient process maintained during the filtration. 
 
With the FAST disc, however, the lower chamber is initially filled with priming liquid. Therefore, 
as the disc rotates, the pressure in the lower chamber also increases until its magnitude is almost linearly 
proportional to the distance from the axis of rotation, in much the same way as in the upper part, as 
shown in Figure 2.8b. This constitutes the critical difference from the non-FAST case. The pressure 
gradient developed in the lower chamber is fairly well matched with that in the upper chamber, giving 
rise to a relatively uniform pressure drop, which induces a uniform flow across the membrane, as shown 




The flow rate Q can be calculated from the pressure drop  and hydrodynamic resistance, .  
 
To maintain a stable and smooth flow during filtration with FAST, the dimensions of the disc 
geometry are an important factor. The effect of the outlet channel resistance and the capacity of the 
priming chamber under the membrane were investigated by using an electric circuit equivalent model 
(Figure 2.9). A low outlet resistance would make the system unstable while a high resistance would 
reduce the flow rate of the system. Furthermore, it was demonstrated that a larger priming chamber was 
more advantageous for attaining a stable flow. 
 
Optimization of FAST disc using cells spiked into whole blood.  
 
To evaluate the FAST disc, we first used a sample of unfixed MCF-7 human breast cancer cells, 
spiked into blood samples taken from healthy donors. As shown in Figure 2.10a, the capture efficiency 
was highest, >95.9 ± 3.1% (mean ± standard deviation [SD], n = 3), at 600 rpm, but fell significantly 
as the spin speed increased (49.9 ± 0.9% at 2400 rpm). Meanwhile, the purity increased marginally 
from 2.5-log depletion (mean: 6,420 WBCs/mL, range: 5,748–7,176 WBCs/mL) at 600 rpm to 2.9-log 
depletion (mean: 2,528 WBCs/mL, range: 1,533–3,392 WBCs/mL) at 2,400 rpm. At spin speeds of less 
than 600 rpm, the centrifugal force was not sufficient to achieve effective filtration. In our previous 
report on a CTCs’ isolation disc operated in non-FAST mode66, a spin speed of higher than 2,400 rpm 
was required to filter whole blood samples whereas 600 rpm proved sufficient in the current FAST disc. 
 
Furthermore, the number of washing steps was further optimized to attain a higher degree of purity. 
When the number of washing steps was increased up to 6, we achieved 3.0-log depletion (mean: 1,636 
WBCs/mL, range: 1,301–2,259 WBCs/mL) with a slightly reduced capture efficiency of 81.8% ± 5.0%, 
giving a degree of purity comparable to that attainable with the immunoaffinity-based positive 
enumeration method82 (Figure 2.10b).  
 
Tests with five cancer cell lines spanning a broad range of EpCAM expressions and sizes (Figure 
2.11), spiked in whole blood demonstrated the efficient capture of viable cells (Figure 2.10c). In 
addition, the excellent reproducibility of the recovery rate, 96.2 ± 2.6%, was confirmed from repetitive 
tests performed over 15 different days with 30 different discs, which suggests that the FAST disc can 
provide a robust method of enumerating CTCs from whole blood (Figure 2.10d). A live/dead assay 










Figure 2.7. Effect of the FAST on the pressure drop, filtration time, and recovery 
of cancer cells from whole blood. (a) Schematic diagram and a photo image of a dis
c for the wireless measurement of the transmembrane pressure while the disc was bein
g spun at 600 rpm to filter the whole blood. A pressure sensor was connected to a da
ta acquisition board and the obtained data were transmitted to a computer by a Blueto
oth module equipped with a data acquisition board. (b) Pressure drop and (c) Decantin
g volume measured during the filtration of whole blood as a function of time. Use of 
the FAST disc enables ultrafast (< 20 s for 3 mL of whole blood) CTC isolation with
 a reduced pressure drop (~1 kPa). (d) The recovery of MCF-7 cells spiked in whole 
blood showed a 95.9% efficiency with a good linearity for the FAST disc, compared t









Figure 2.8. Numerical analysis comparing non-FAST and FAST disc methods. (a) Blood 
phase flows (left) and pressure contours (right) at 0.13 s, induced by centrifugal force generated 
by spinning the disc at 600 rpm in non-FAST (top) and FAST (bottom) modes. Pressure is 
developed due to centrifugal force in O (1 kPa), which is determined by the mass of the liquid 
phases and the angular velocity of rotation. In the non-FAST case, the pressure gradient in the 
upper chamber causes a non-uniform pressure drop across the membrane and, in consequence, 
the blood phase is filtered only through a small portion of the membrane. This significantly 
reduces the efficiency of the membrane. Meanwhile, in the FAST disc, the chamber under the 
membrane is filled with an aqueous phase during the entire filtration process. Therefore, when 
the blood phase reaches the membrane, the blood phase flows into the lower chamber uniformly 
and diffuses into and mixes with the liquid phase. The FAST disc uses the entire membrane area 
for filtration which significantly alleviates clogging. (b) Pressure plots in the radial direction 
above (1) and below (2) the membrane. (c) Pressure difference (∆p = p1 – p2) along radial 
direction. The broken lines correspond to the non-FAST cases (b,c) indicate those locations 





Figure 2.9. Electric circuit equivalent model for non-FAST and FAST methods. Electric circuit 
equivalent models for (a) non-FAST and (b) FAST methods. (c) Effect of outlet resistance (R2) in non-
FAST method, which varies with the channel width. If the outlet resistance is too low (blue line), back 
flow may be possible, making system unstable. If the outlet resistance is too high (black line), the flow 
rate is significantly reduced. (d) Capacitance effect of lower chamber in non-FAST method. If the 
capacitance increases, the flow rate of the outlet stabilizes. If there is no air in the lower chamber (FAST 
method), the flow is almost incompressible and so can spontaneously respond to the flow rate while the 
system is running. These hydrodynamic behaviors should be considered to optimize the chamber 










Figure 2.10. Optimization of the FAST disc using cancer cells spiked into whole blood. The 
capture efficiency (red); defined as number of captured cancer cells/input number of cancer cells, 
and purity (blue); log depletion ratio defined as log (input number of white blood cells 
[WBCs]/number of remaining WBCs on the membrane), were evaluated with MCF-7 cells 
spiked into whole blood at various (a) rotational speeds and (b) numbers of washing steps. The 
spin speed was held at 600 rpm and two washes were used for the follow-up experiments with 
cells spiked in whole blood. For the molecular analysis, six washes were used to achieve the 
>3.0-log depletion of WBCs. (c) Capture efficiency test with five cancer cell lines spanning a 
broad range of EpCAM expressions and sizes produced a > 96% capture efficiency with the 
FAST disc. (d) Reproducibility tests with spiked cells (10–100 MCF-7 cells) in whole blood 
conducted for fifteen days using 30 different discs showed 96.2 ± 2.6 % (mean ± SD) recovery. 
(e) Live/dead assay result for captured cells (AGS) on a FAST disc after being cultured for 15 













Figure 2.11. EpCAM expressions and sizes of five cancer cell lines. (a) EpCAM expression as 
confirmed by real-time PCR and normalized to GAPDH. MDA-MB-231, MDA-MB-436 breast cancer 
cells and AGS stomach cancer cells exhibited a low expression while HCC78 lung cancer cells exhibited 
a high expression compared to MCF-7 breast cancer cells. (b) Cell diameters of various cell lines were 
measured; MDA-MB-231 (13.4 ± 3.3 μm), MDA-MB-436 (12.2 ± 1.5 μm), AGS (12.4 ± 1.7 μm), 







Figure 2.12. Results of live/dead assay after the filtration and 15 days culturing. The cell viability 
(97.6 ± 0.4%) was confirmed immediately after filtration by live/dead assay. Images show that there 
are only live cells (a) and no dead cells (b). Scale bar: 20 μm. (c-f) Various kinds of cancer cells captured 
on the membrane by the FAST disc were incubated for 15 days. Images show the results of live/dead 
assay with the incubated cells of MDA-MB-231 (c), MDA-MB-436 (d), MCF-7 (e), and HCC78 (f). 




Comparison with other size-based filtration methods.  
The degree of CTC isolation with the FAST disc was first compared with a commercially available 
size-based filtration device, ScreenCell Cyto, using MCF-7 cells spiked in whole blood (Figure 2.13a). 
The capture efficiency was 95.9 ± 3.1% (n = 3, unfixed, whole blood) and 68.9 ± 10.0% (n = 3, diluted 
with a buffer for RBC lysis and fixation) for FAST discs and ScreenCell, respectively. FAST disc was 
found to provide a higher purity of 2.5-log (mean: 4,771 WBCs/mL, range: 4,330–5,483 WBCs/mL) 
compared to 1.7-log (mean: 32,950 WBCs/mL, range: 29,550–37,137 WBCs/mL) depletion. 
 
In order to make direct performance comparisons of ScreenCell and FAST using clinical samples, 
two aliquots of the blood samples from each patient were tested with a FAST disc and a ScreenCell 
Cyto device under their corresponding recommended protocols. Using the conventional criteria for CTC 
identification, DAPI+, EpCAM/CK+, and CD45- (Figure 2.13b and Figure 2.14), FAST discs could 
detect at least one CTC from 14 out of the 16 patients with different cancer types (detection rate: 87.5%, 
mean: 18 CTCs/7.5 mL, median: 8 CTCs/7.5 mL, range: 0–90 CTCs/7.5 mL), while ScreenCell Cyto 
devices detected 8 out of the 16 samples (detection rate: 50.0%, mean: 12 CTCs/7.5 mL, median: 4 
CTCs/7.5 mL, range: 0–90 CTCs/7.5 mL). Meanwhile, the number of WBCs remaining on the 
membrane identified by using the criteria of DAPI+, EpCAM/CK-, and CD45+ was 6.0 times higher 
with ScreenCell (mean: 30,339 WBCs/7.5 mL, median: 24,152 WBCs/7.5 mL, range: 13,407–58,312 
WBCs/7.5 mL) than that with the FAST disc (mean: 5,075 WBCs/7.5 mL, median: 4,955 WBCs/7.5 
mL, range: 1,923–9,249 WBCs/mL). Taken together, we were able to demonstrate that the FAST disc 
could provide CTCs with a higher recovery rate and higher level of purity from clinical samples (Figure 
2.13c and Table 2.1). 
 
Immunohistochemical and molecular analyses of CTCs from patients.  
After the validation of the FAST disc platform, we analyzed blood samples from patients with 
different types of cancer (n = 142) as well as from healthy individuals (n = 50) as controls (Figure 
2.13d, Figure 2.15 and Table 2.2). The clinical samples were collected from Pusan National University 
Hospital (PNUH) according to the approved IRB process. CTCs (mean: 58 CTCs/7.5 mL, median: 13 
CTCs/7.5 mL, range: 0–540 CTCs/7.5 mL) were detected from 83.3% (15/18) of breast cancer patients 
with various stages while 50 healthy subjects had negligible CTC counts (mean, 0 CTCs/7.5 mL; 
median, 0 CTCs/7.5 mL; range, 0–5 CTCs/7.5 mL). Moreover, 63 of the 76 samples (82.9%) obtained 
from stomach cancer patients contained CTCs within a range of 2–485 CTCs/7.5 mL (mean: 21 
CTCs/7.5 mL, median: 4 CTCs/7.5 mL). Due to the unique characteristics of the early diagnostics of 
stomach cancer by the National Cancer Screening Program in Korea, majority of the patients, 54 of the 








Figure 2.13. Performance comparison with the commercially available size-based 
filtration system and clinical test of FAST disc. (a) Capture efficiency and purity were 
compared for the results of the filtration experiments with MCF-7 cells spiked in blood samples. 
Whole blood was directly filtered through membranes with 8.0 m pores with the FAST disc. 
The samples were diluted and prefixed according to the manufacturer’s recommended protocol 
for the ScreenCell Cyto device, and were then filtered through membranes with 7.5 m pores 
by the application of negative pressure provided by a vacuum tube. (b) Fluorescence images of 
isolated CTC obtained from a patient’s blood sample (Scale bar: 8 m). (c) Performance 
comparison with FAST disc and ScreenCell by using clinical samples obtained from patients 
with cancer of the breast (n = 3), stomach (n = 4), colon (n = 4), bile duct (n = 3), and lung (n = 
2). All counts were normalized to 7.5 mL.  (d) Number of CTCs isolated from blood samples 
of healthy donors (H, n = 50), patients with cancer of the breast (B, n = 18), lung (Lu, n = 35), 
stomach (S, n = 76), bile duct (BD, n = 3) gallbladder (GB, n = 4), liver (Li, n = 3), and pancreas 
(Pa, n = 3). (e) Number of CTCs from lung cancer patients with/without distant metastasis was 
compared with healthy donors. (f) EGFR real-time PCR assay was performed using the cells 
captured on membrane from blood samples of two lung cancer patients with the L858R and 19-
Del mutations. Blue line is for internal control and red line is for the target sample. Negative 










Figure 2.14. The fluorescence images of the membrane after the isolation of CTCs from the blood 
of a cancer patient. CTCs captured by size-based isolation using (a) FAST disc and (b) ScreenCell 
were immunostained. The blue, green, and red signals are from DAPI+, CK+ or EpCAM+, and CD45+ 
cells, respectively. The filter membranes were retrieved to acquire the fluorescence images. It is noted 
that the number of WBCs (DAPI+, EpCAM-, CK-, and CD45+) from a FAST disc is significantly 
smaller than that from ScreenCell. The circles in the left pictures show the whole area of the membrane 
with the diameter of 10 mm and 6 mm for a FAST disc and a ScreenCell, respectively. The red dot 
squares are zoomed to show an enlarged view of the corresponding area in the middle and right images. 














Table 2.1. Comparison of CTC detection in cancer patient’s blood using FAST disc and 
ScreenCell. CTCs were isolated from the blood of 16 cancer patients and the number of CTCs was 








Figure 2.15. Prevalence of CTCs from patients with breast cancer (n = 18), stomach cancer (n = 
76) and lung cancer (n = 35) (a) CTCs (mean: 58 CTCs/7.5 mL, median: 13 CTCs/7.5 mL, range: 0–
540 CTCs/7.5 mL) were detected from 83.3% (15/18) of breast cancer patients. (b) In the case of 
stomach cancer patients, 63 of the 76 samples (82.9%) contained CTCs within a range of 2–485 
CTCs/7.5 mL (mean: 21 CTCs/7.5 mL, median: 4 CTCs/7.5 mL). (c) CTCs (mean: 10 CTCs/7.5 mL, 



















Table 2.2. Number of CTCs isolated from blood samples of healthy donors and cancer patients. 
CTCs were isolated from blood samples of 50 healthy donors and 142 cancer patients and the number 












Figure 2.16. Examples of images of CTCs isolated from blood of patients with breast cancer, 
stomach cancer, and lung cancer. DAPI+, EpCAM/CK+, and CD45- cells are classified as CTCs. 
(Scale bar: 8 m).  
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were in relatively early stages (I/II) and all patients were without distant metastasis, highlighting that 
our FAST disc might be potentially useful for the early detection of solid tumors. 
 
In the case of lung cancer, the CTCs (mean: 10 CTCs/7.5 mL, median: 4 CTCs/7.5 mL, range: 0–
62 CTCs/7.5 mL) could be detected in 68.6% (24/35) of the patents and the patients with long distance 
metastasis have significantly higher number of CTCs (Figure 2.13e). Example fluorescence images of 
the CTCs isolated from cancer patients are shown in Figure 2.16. 
 
Beyond immunostaining and counting, molecular analyses are increasingly being practiced in CTC 
characterization, which is expected to improve personalized therapy.54, 82 As a proof of concept 
experiment, a real-time polymerized chain reaction (PCR) was performed to detect somatic mutations 
in the epidermal growth factor receptor (EGFR) gene to select non-small-cell lung cancer (NSCLC) 
patients who are predicted to respond to targeted therapy such as EGFR tyrosine kinase inhibitors (e.g., 
gefitinib or erlotinib). The PC9 lung cancer cells spiked in whole blood were processed with a FAST 
disc and the lysate of the captured cells on the membrane was used as the subject for DNA preparation 
followed by real-time PCR. Mutation was detected with a success rate of 50.0% (3/6) and 100.0% (6/6) 
for 10 and 100 cells spiked in 3 mL of whole blood, respectively. The estimated purity is in the order of 
0.1% and 1.0% for 10 and 100 cells spiked in 3 mL of whole blood, respectively since log depletion of 
WBC with FAST disc is demonstrated to be about 3.0.  
 
Similarly, KRAS mutation analysis, which is often recommended to test the drug resistance of 
targeted medicines such as tyrosine kinase inhibitors, was conducted with H358 lung cancer cells spiked 
in whole blood. The use of the FAST disc followed by real time PCR could detect 10 and 100 cells 
spiked in 3 mL of whole blood with a 50.0% (3/6) and 100.0% (6/6) success rate, respectively. In 
addition, the mutation analysis was further confirmed with two clinical samples from lung cancer 
patients with L858R or 19-Del EGFR mutations (Figure 2.13f). It is important to note that the total 
process of CTC isolation from whole blood followed by the molecular analysis took less than 2 h, which 
can be potentially useful in clinical settings.  
 
2.2.4 Conclusions 
We introduce an ultrafast, user-friendly, and highly sensitive centrifugal microfluidic technology, 
the FAST disc, which can isolate live CTCs with good purity from the unprocessed whole blood of 
cancer patients. Existing size-based technologies exhibit lower sensitivity and specificity and often 
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require additional sample pretreatment steps and/or expensive lithographic microfilters to improve the 
capture efficiency of CTCs from blood samples.57-63, 65 In conventional pressure-driven filtration, it is 
highly possible that only a small portion of the membrane might be actively used for the filtration. This 
decreases the overall efficiency of the filtering process and, furthermore, it will probably encounter 
clogging, which aggravates the filtering efficiency. If the clogging persists, a higher pressure difference 
is required to filter the blood cells over a long time, but it is not desirable for cells to be exposed to such 
high shear conditions. Meanwhile, with the FAST disc, the chamber under the membrane is filled with 
an aqueous phase prior and during the entire filtration process. Therefore, when the blood phase reaches 
the membrane, the blood phase flows down to the lower chamber uniformly and diffuses in the aqueous 
phase. The FAST disc uses the entire membrane area for filtration and greatly alleviates clogging issues. 
 
Using the FAST disc, we could achieve a remarkable enhancement in the CTC capture yield and 
purity in size-based filtration, even when using a track-etched membrane. From the MCF-7 cells spiked 
in whole blood, we could detect CTCs with a 96.2 ± 2.6% recovery rate from repetitive tests conducted 
for more than 15 days with 30 different discs. A compact stand-alone instrument for user-friendly 
operation of the disc was custom-designed and used to test clinical samples taken from 50 healthy 
donors and 142 cancer patients. While the number of CTCs detected in the samples taken from the 
healthy subjects was negligible, the FAST disc was able to detect 0–540 CTCs/7.5 mL CTCs from 15 
of the 18 (83.3%) samples taken from breast cancer patients and 2–485 CTCs/7.5 mL taken from 63 of 
76 (82.9%) stomach cancer patients. It is important to note that all of the breast and stomach cancer 
patients in this study were without distant metastases. Although there are many reports on the 
importance of CTCs as a new biomarker for cancer metastasis,83 few studies have so far been done to 
determine whether CTCs are also useful for the early detection of solid tumors.84, 85 With highly 
sensitive, cost-effective and robust FAST disc technology, we could detect a significant number of CTCs 
not only from cancer patients with metastasis but also from patients in relatively early stages of cancer 
without distant metastases, which gives rise to the potential of CTCs being used as an early diagnostic 
marker. Furthermore, the CTCs isolated by the FAST disc are not fixed but instead are alive, allowing 
them to be readily used for standard analyses such as immunostaining, high-resolution imaging, and 
mutation analysis, which are particularly important for personalized therapy. Because the FAST disc 
mechanism can be applied to a variety of size-based filtration techniques, we expect it to prove useful 




Chapter 3. Single cell analysis of isolated CTCs by using FAST disc 
3.1 Introduction 
Lung cancer is the most common cause of cancer-related mortality in both men and women 
worldwide 86, 87. Non-small cell lung cancer (NSCLC) accounts for 84% of all lung cancers, and despite 
improved diagnostic techniques, a great majority of patients with NSCLC present with advanced-stage 
tumors at diagnosis, and the 5-year relative survival rate is less than 20% 88. Epidermal growth factor 
receptor (EGFR) mutations are found in310–30% of patients with NSCLC, and targeted therapies, 
including EGFR-tyrosine kinase inhibitors (TKIs) can deliver significantly improved clinical outcomes, 
depending upon the type of mutation 4, 89. As new-generation EGFR-TKIs (e.g. osimertinib) 90, 91 have 
been developed recently for patients who showed resistance to conventional EGFR-TKIs, frequent 
examination of the tumor susceptibility to EGFR-TKIs became very important. However, conventional 
tissue biopsy is invasive, and therefore, more facile and less invasive liquid biopsy methods, able to 
monitor the disease response to targeted therapy and track the emergence of drug resistance, could 
significantly aid in the clinical management of the disease. 
 
Among various circulating biomarkers, circulating tumor cells (CTCs) offer a unique opportunity 
to obtain information on live tumor cells at the DNA, RNA, and protein levels. Despite significant 
challenges associated with the extremely rare and heterogeneous characteristics of CTCs, recent 
technological advancements have allowed studying the prognostic value of CTCs, as well as monitoring 
and predicting the efficacy of therapy. To date, various platforms have been developed to isolate CTCs 
based on their biochemical or physical properties, such as the expression of epithelial cell adhesion 
molecule (EpCAM) or their size. Nevertheless, only the CellSearch™ system (Menarini Silicon 
Biosystems) is currently approved by the US Food and Drug Administration for the enumeration of 
CTCs in patients with metastatic colorectal 92, breast 93, and prostate 94 cancer. However, the prognostic 
value of CTCs remains controversial in NSCLC. Although many previous studies have demonstrated 
that patients with a higher number of CTCs have a poor clinical outcome 28, 95-99, some studies have 
reported that baseline CTC counts had no significant correlation with the survival rate in patients with 
NSCLC 100, 101. 
 
Previous immunoaffinity-based CTC enrichment methods using anti-EpCAM antibodies suffer 
from the limitation of missing clinically important CTCs with low EpCAM expression such as 
* Chapter 3 is reproduced with the permission from “M. Lim†, J. Park†, A.C. Lowe; H. Jeong; S. Lee; H.C. Park; 
K. Lee; G.H. Kim; M.-H. Kim; Y.-K. Cho, Theranostics 2020, 10, 5181-5194.” Copyright 2020 Ivyspring 
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mesenchymal and stem cell-like tumor cells. Furthermore, immunoaffinity-based isolation methods 
require a relatively long processing time to achieve an efficient antigen–antibody interaction 102, 103. 
Alternatively, marker-independent approaches, based on intrinsic physical properties of CTCs, have 
been developed 104, 105, but they tend to show lower capture yields and purity, and sample pretreatment 
requirements or clogging issues are often a problem. Size-based CTCs isolation methods using inertial 
microfluidics provide relatively high detection rates but require prior sample preparation steps such as 
removal of red blood cells and dilution 106, 107. While most of the current CTC enumeration technologies 
rely on signal averaging across individual heterogeneous CTCs, facile analysis of CTCs at a single-cell 
resolution is highly desired to assess the cell heterogeneity and uncover its clinical consequences. 
Although much progress has been made and clinical significance of CTCs has been demonstrated, the 
remaining challenges include a high cost, low throughput, and complexity of the process, as well as 
false-positive/false-negative results, which hinder a wider adoption of CTC-based liquid biopsy as a 
routine practice in clinical settings.  
 
In this report, we present the preclinical validation of a fluid-assisted separation technology 
(FAST) disc 108, which allows rapid (>3 mL/min), reproducible, and label-free isolation of CTCs 
directly from unprocessed whole blood of patients with NSCLC. We performed serial monitoring of 
CTC counts, mutation detection, and single-cell multiplex gene expression of CTCs from a prospective 
cohort of patients with NSCLC receiving EGFR-TKIs treatment. The study highlights the potential of 
a CTC-based liquid biopsy for assessing the efficacy of therapy and emergent drug resistance. 
 
3.2 Prognostic values of CTCs through single cell analysis 
3.2.1 Experimental details 
Study design and blood sample collection 
The biospecimens and data used in this study were provided by the Biobank of the Pusan National 
University Hospital (PNUH), a member of the Korea Biobank Network. The study protocol was 
reviewed and approved by the Institutional Review Board (IRB) of PNUH (H1612-019-049). This was 
a prospective, single-center study conducted at PNUH (Busan, Republic of Korea). Patients who met 
the following inclusion criteria were selected for the study: 1) a histologically or cytologically 
confirmed diagnosis of primary NSCLC; 2) a confirmed EGFR mutation in histological or cytological 
specimens; 3) previously untreated stage IIIB or IV according to the 7th edition of TNM staging system 
by the international association for the study of lung cancer [measurable disease according to Response 
Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)]; and 4) received at least one dose of 
EGFR-TKIs as the first-line therapy during the follow-up study. Blood samples were collected for 
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analysis within 3 days before/after EGFR-TKIs treatment. Written informed consent was obtained from 
all patients before blood sampling.  
To monitor CTC counts during TKI therapy, blood samples were collected from 40 enrolled 
patients on a regular schedule. Peripheral blood (3 mL) was collected in a Vacutainer® (K2 EDTA, 
#367844; BD Medical) and CTC isolation was completed within 6 h 109-111. For the detection of EGFR 
mutations and single-cell-level gene expression analysis, additional 3 mL blood samples were collected 
from 16 patients. For serial monitoring of single-cell RNA expression in CTCs, blood samples were 
collected from 75-year-old male (LP25) and 74-year-old female (LP38) patients diagnosed with 19del 
and L861Q EGFR mutant-positive lung cancer, respectively, who were receiving afatinib treatment.  
Cell culture 
Breast cancer (MCF7, MDA-MB-231, and SKBR3), prostate cancer (LNCaP and PC3), and lung cancer 
(H460, H2228, HCC78, and PC9) cell lines were purchased from the American Type Culture Collection. 
All cell lines were cultured in RPMI 1640 medium supplemented with 5% FBS and 1% 
antibiotics/antimycotics at 37°C, 5% CO2. The mycoplasma test was confirmed by e-MycoTM  
Mycoplasma detection kit (Intron, Korea). 
Immunofluorescent staining and analysis of CTCs  
Immunofluorescent staining and detection were performed on the FAST disc membrane according to a 
previously reported protocol 108. Briefly, CTCs captured on a FAST disc were fixed with 4% 
formaldehyde and permeabilized with 0.1% Triton X-100, followed by washing and blocking with 10 
μg/mL IgG in PBS. Cells were identified using a three-color immunofluorescence method, including 
FITC-conjugated anti-cytokeratin (CK) and anti-EpCAM markers for epithelial cells, a PE-conjugated 
anti-CD45 marker for white blood cells (WBCs), and DAPI for nuclear staining. Cells that were CK+ 
or EpCAM+, CD45−, DAPI+, and morphologically intact were identified as CTCs, while cells that 
exhibited high CD45 expression levels were identified as WBCs. Fluorescently stained cells were 
automatically scanned on a slide using a BioView workstation (BioView, Inc.) for the FAST disc. 
CTC isolation and analysis using CellSearch 
CTC enumeration, immunofluorescent staining, and detection by the CellSearch epithelial cell test 
(Menarini Silicon Biosystems, Inc.) were performed using the CellSearch™ protocol 
(www.cellsearchctc.com) at the Brigham and Women's Hospital (BWH), Boston, MA (The BWH IRB 
number is 2016P001708). A FAST disc operation system was shipped to BWH and used for a direct 
comparison with CellSearch. Two blood samples were collected from 17 enrolled patients with cancer 
into two types of tubes: 7.5 mL of whole blood in CellSave tubes (Menarini Silicon Biosystems, Inc.) 
for CellSearch and 3 mL of whole blood in EDTA tubes for FAST disc detection. The enumeration of 
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CTCs was performed using the recommended protocols for each method, as described previously 108, 
112, 113. 
DNA mutation analysis 
To detect mutations in isolated CTCs, genomic DNA was extracted using the QIAamp DNA blood mini 
kit (Qiagen). For the detection of L858R, 19del and T790M mutations in gDNA, PCR was performed 
using the following cycling conditions on a Master cycler pro S instrument (Eppendorf): 95 °C for 10 
min, followed by 40 cycles of 95 °C for 30 s and 58 °C for 1 min, and 98 °C for 10min, then held at 
4 °C. The PCR mixture (20 μL) contained 10 μL of ddPCR supermix for probes, no UTP (Bio-Rad), 1 
μL of 20× primer/probe assay for mutant and wild type (Bio-Rad), and 8 μL of DNA. The copy number 
of mutants was quantified using the QuantaSoft software (QX-200, Bio-Rad). 
Statistical analysis of CTC enumeration data 
Overall survival (OS) and progression-free survival (PFS) were chosen as the endpoints to evaluate 
the prognostic value of CTC counts. The survival time was estimated using the Kaplan–Meier method, 
and the difference in survival between groups was assessed using a log-rank test. The SPSS 22.0 for 
Windows software was used for statistical analyses. To confirm the correlation between the CTC count 
change ratio;  where CTCi is the CTC count at time point i and 
CTC0 is the baseline CTC count and imaging response results, a two-tailed Student’s t-test with a 95% 
confidence interval was performed using Origin 2015 (OriginLab Corp.). P-values < 0.05 were 
considered statistically significant. 
Single-cell isolation and multiple gene expression analysis 
Single cells were isolated using Kuiqpick™ (NeuroInDx). Cells captured on the membrane were 
stained for CD45, EpCAM, and DAPI to identify target cells. Single-cell cDNA was prepared using the 
Single Cell-to-Ct kit (Life Technologies), and a specific target was preamplified for gene expression 
analysis. qRT-PCR was performed using a BioMarkHD real-time PCR system and the software 
(Fluidigm). For analysis, quality thresholds of 0.65 and Ct ≤ 30 were considered.  
Undetected genes were assigned a Ct-value of 999, which was imputed as the highest Ct-value 
observed for a given gene plus a value of 1 to provide balanced weights to missing data. All imputed 
Ct-values were converted to Z-scores to provide the same weights 114. To assign equal weights to all 
measured mRNAs, the gene expression values were mean-centered and Z score-transformed by 
dividing the mean-centered expression value by the standard deviation. We conducted unsupervised 
hierarchical clustering and t-distributed stochastic neighbor embedding (t-SNE) to explore associations 
among sample groups. Unsupervised hierarchical clustering and its heatmap visualization were 
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performed using the heatmap.2 function of the gplots package, and t-SNE analysis was performed using 
the Rtsne package in R (version 3.4.0). 
 
Correlation matrix plots were constructed using the corrplot function in R. Correlation matrices 
were computed separately for patient-derived CTCs, cancer cell lines, and WBCs, with Spearman’s 
rank correlations. Associated P-values were computed using the cor.mtest function in R. The Bonferroni 
correction of P-values was performed to adjust for multiple testing in the rank correlation matrix.  
CTC classification 
Based on the gene expression profiling data for individual cells, we calculated their epithelial (E) 
or mesenchymal (M) scores. Epithelial markers such as EpCAM and CK markers (KRT7, KRT18, and 
KRT19) were selected to measure scores related to epithelial characteristics of CTCs. The mesenchymal 
markers vimentin and CD44 were selected to calculate M-scores of CTCs. The mRNA expression 
values of the target markers, normalized to those of GAPDH using the 2−ΔCt method, were added up for 
each E/M group, and the relative percentage was used to classify CTCs according to their epithelial-to-
mesenchymal transition (EMT) characteristics. 
 
 
3.2.2 Results and discussion 
Label-free isolation of CTCs from whole blood using FAST disc 
A FAST disc is a centrifugal microfluidic device, which enables clog-free, label-free CTC 
isolation from whole blood 108 (Figure 3.1a). In a FAST disc, the fluid flow by centrifugal force and 
that by filtration through the membrane are in perpendicular directions, similar to the tangential-flow 
filtration, which minimizes clogging (Figure 3.1b). The operation of the FAST disc is very simple and 
fast: 1) add 3 mL of whole blood to the sample-loading chamber; 2) spin the disc using a tabletop-sized, 
portable spinning machine; and 3) add 1 mL of washing buffer and spin. The total process of the 
isolation of CTCs from 3 mL of whole blood could be finished within 1 minute (Figure 3.1c). The CTC 
enumeration was performed using the conventional criteria for CTC identification, EpCAM/CK+ and 
CD45−, with immunofluorescence staining performed on the disc (Figure 3.1d and Figure 3.2). 
Compared with a commercially available product, the CellSearch system (Menarini Silicon 
Biosystems, Inc.), the FAST disc showed a high capture efficiency, irrespective of the EpCAM 
expression levels in the cell lines, while CellSearch showed a high capture efficiency only for cell lines 
with high EpCAM expression (Figure 3.1e). Further, clinical tests using blood samples from 17 patients 








Figure 3.1. Workflow, mechanism, and performance of FAST disc. (a) Visualization of the FAST 
disc before and after the CTC enumeration process. (b) The centrifugal force pushes the liquid in a 
tangential direction to the flow filtering through the membrane. (c) Size-based isolation of CTCs from 
whole blood (3 mL) can be completed within 1 min, all in one disc. After washing and staining for 
enumeration, the filter can be removed and mounted on a slide glass for downstream analysis. (d) 
Representative images of CTCs (DAPI+, EpCAM/CK+, CD45-) isolated from the blood of cancer 
patients. (e) Performance comparison between the CellSearch system and FAST disc using whole blood 
spiked with cancer cells (<100). Five cell lines with various EpCAM expression levels were used to 
quantify the recovery rates. (f) CTCs enumerated by the CellSearch system and FAST disc from the 
blood samples of 17 patients with different cancer types. (g) Reproducibility test using blood samples 








Figure 3.2. Fluorescence images of patient-derived CTCs. Representative examples of (a) patient-
derived CTCs from two different NSCLC patients (Scale bar: 10 μm) and (b) CTC clusters from 
NSCLC patients (Scale bar: 8 μm). Merged images and three images from different fluorescent channels 




outperformed the immunoaffinity-based enumeration by CellSearch; the detection rates were 94.1% 
and 11.8%, respectively. In addition, the failure rates were much lower for the FAST disc than for 
CellSearch, 5.9% and 23.5%, respectively (Figure 3.1f). Measurement of CTCs in two blood samples 
collected from the same patient confirmed a good reproducibility of the FAST disc platform, which is 
a prerequisite for continuous monitoring of the disease status (Figure 3.1g). 
 
Clinical characteristics of the prospective cohort of patients with NSCLC receiving EGFR-TKIs 
treatment 
A total of 340 blood samples were obtained from 40 patients diagnosed with NSCLC with EGFR 
mutations at different treatment time points for CTC isolation using the FAST disc platform; a summary 
of the patients’ baseline characteristics is shown in Table 3.1. At the time of analysis, 22 of the 40 
patients (55.0%) experienced disease progression, and 12 patients (30.0%) died or were lost to follow-
up, resulting in a median PFS of 13.1 months (95% CI: 11.7‒16.3 months) and OS of 19.0 months (95% 
CI: 15.6‒20.2 months). The average follow-up time for the 28 patients who were still alive was 19.6 
months (range: 9.8‒31.3 months). 
 
Baseline CTC counts and survival 
The median CTC0 value among 38 tested patients was 37 CTCs/7.5 mL. With the cutoff value of 66 
CTCs/7.5 mL, which minimized the p-value from the log-rank test, eight patients (21.1%) showed CTC 
counts higher than the cutoff (CTCHigh group). Thirty patients (78.9%) showed CTC counts lower than 
the cutoff (CTCLow group). As shown in Figure 3.3a, the CTCLow group had a relatively longer OS than 
did the CTCHigh group, but the difference was not statistically significant. Thus, no correlation was 
observed between CTC0 and OS. One possible reason is that the efficacy of the first-line therapy, rather 










Table.3.1 Patients demographics and clinical characteristics 
Characteristics No. (%) 
















































Figure 3.3. Correlation between CTC counts and treatment responses on CT scans. (a) Kaplan-
Meier curves for OS between two patient groups according to the cutoff baseline CTC count (66 
CTCs/7.5 mL). (CTCLow: n = 30, median OS: 18.04; CTCHigh: n = 8, median OS: 15.46, log-rank p 
= 0.3501; samples from two patients had a clogging issue.) (b) Six of 40 patients (15%) did not respond 
well to their first choice of therapy and had to change the treatment option more than once, resulting in 
a significantly poorer PFS than that of patients who responded well to the first-choice drug. Kaplan-
Meier curves for PFS between two patient groups according to the number of treated drugs. (N = 1: n 
= 34, median PFS: 25.70, N > 1: n = 6, median PFS: 9.65, log-rank p = 0.0039). (c) Kaplan-Meier 
curves for OS between the two patient groups according to the number of treated drugs, demonstrating 
no significant difference. (N = 1: n = 34, median OS: undefined, N > 1: n = 6, median OS: 28.50, log-




Serial monitoring of CTC counts 
We next focused on the trends of CTC counts to evaluate the correlation with patients’ disease 
burden and treatment response, as shown in Figure 3.4. A cohort of 11 patients who had the 19del 
mutation and were enrolled for more than 19 months was used to evaluate the correlation of CTC counts 
with the treatment response. The RECIST criteria (version 1.1) were used to assess the treatment 
response via computed tomography (CT) scans acquired every two or three cycles, and responses were 
classified as a complete response (CR), partial response (PR), stable disease (SD), or progressive 
disease (PD) 115. When we compared the change rate of the CTC counts as a function of the imaging 
response results, the PD group (average 70.1% increase, N=17) showed a significantly higher CTC 
count change rate than did the PR group (average 43.1% decrease, N=24). 
 
Detection of EGFR mutations in tumor tissue and CTCs isolated using the FAST disc 
We evaluated the concordance rate in detecting mutations in tumor tissue and CTCs isolated 
from blood samples. In 15 samples from 13 patients, the mutations identified in CTCs were 100% 
consistent with those found in the matching tumor tissues. Interestingly, the EGFR T790M mutation 
was detected in both relapsed tissue and CTCs isolated from blood samples of two patients, LP2 and 
LP49, who did not show this mutation during their first biopsy using both tumor tissue and blood 
samples, as summarized in Table 3.2. 
 
Single-cell RNA expression analysis of patient-derived CTCs 
To characterize the tumor heterogeneity, we applied a single-cell manipulation technique to isolate 
patient-derived live CTCs. After blood filtration and immunostaining for CD45 without a fixation step, 
live CTCs captured on the membrane were collected, and individual cells without a CD45 signal were 
subjected to single-cell RNA expression analysis (Figure 3.5 and Figure 3.6). 
 
We assessed mRNA expression in individual cells isolated from the four lung cancer cell lines, 
H2228, H460, HCC78, and PC9 (Figure 3.7), and from the blood samples withdrawn from three 










Figure 3.4. Representative examples of CTC counts and CT images obtained during the course of 
treatment and their correlations. (a) Tumor size and CTC counts show an increase in the tumor 
burden during 582 days of various EGFR-TKI treatments for patient LP2. (b) Patient LP11 continued 
to receive erlotinib initially. The CTC counts from the blood draw at 301 and 378 days were significantly 
increased with PD determined from CT images obtained on days 294 and 378. After the treatment was 
changed to alimta, both the CTC counts and tumor burden decreased dramatically and PR was 
determined at day 462. (c) Relationships with the change rate of CTC counts, CTC (%); CTC counts 
change normalized by the baseline CTC, and CT scan image response results from patients with a 19 
del mutation who enrolled in the follow-up monitoring study for more than 19 months. The CTC count 
change rate is sorted according to the imaging response results (PD or PR). The PD group showed a 







Table.3.2 Detection of EGFR mutation from CTCs. The mutation detection results from CTCs 
isolated from total 13 patients were in 100% concordance with the corresponding results obtained from 
tissue biopsy sample. Notably, T790M, the acquired resistance EGFR mutation, detected at relapse (AR) 
of samples, but not before the treatment (BT), from two patients (LP49 and LP2) both from noninvasive 
blood-based CTC analysis as well as tumor biopsy. 
Patient Sex Age Stage 
L858R T790M 
Tissue CTC Tissue CTC 
LP1 F 52 IV + + - - 
LP5 M 49 IV + + - - 
LP6 M 58 IV + + - - 
LP8 F 76 IV + + - - 
LP10 M 63 IV + + - - 
LP12 F 90 IV + + - - 
LP13 F 53 IV + + - - 
LP46 F 67 IV + + - - 
LP47 F 83 IV + + - - 
LP49 (BT) F 65 IIIA + + - - 
LP49 (AR) F 65 IIIA + + + + 
Patient Sex Age Stage 
19 del T790M 
Tissue CTC Tissue CTC 
LP2 (BT) M 53 IV + + - - 
LP2 (AR) M 53 IV + + + + 
LP25 M 74 IV + + - - 
LP43 F 59 IV + + - - 











Figure 3.5. Procedures for single cell picking. (a) Schematic image of single cell picking. The 
membrane was separated from the disc and mounted onto the glass with the PDMS reservoir containing 
PBS. Using a capillary connected with a pump, a single cell was picked by the vacuum-assisted method. 
(b) Fluorescence images of a cell before and after picking from the membrane. DAPI+/CD45- stained 
cells are candidates for analysis. Image set of DAPI, CD45, and EpCAM before picking showing the 





Figure 3.6. Gene expression profiles of single CTCs isolated from three patients with lung cancer 
and from lung cancer cell lines. (a) Heat map for the hierarchical clustering of the differentially 
expressed genes of single cells from four different NSCLC cell lines [H2228 (orange), H460 (purple), 
HCC78 (brown), and PC9 (green)], WBCs (black), and CTCs from three patients [LP25 (red), LP38 
(blue), and LP39 (cyan)]. Each row represents a single-cell sample. The scale bar indicates the Z-scores 
of gene expression values, with highly expressed genes depicted in red and low-expressed genes 
depicted in green. (b) Two-dimensional t-SNE analysis based on hierarchical clustering. Cells clearly 
grouped according to the sample source. (c) Gene expression data of individual cells were further 
characterized to show an epithelial or mesenchymal cell signature. Intra- and intercellular heterogeneity 
is demonstrated using four different NSCLC cell lines, and profiling of individual CTCs isolated from 
three patients with NSCLC patients before chemotherapy. Patients LP25 and LP39 carried an 19del 




Figure 3.7. Single-cell real-time PCR using various lung cancer cell lines. Single-cell mRNA 
expression of four lung cancer cell lines, H2228, H460, PC9, and HCC78, determined using 
BiomarkHD qRT-PCR. After picking individual cells captured on the membrane by a cell-picker, RNA 
was extracted and preamplified for single-cell mRNA expression analysis. Ct ≤ 30 with a Fluidigm real-
time PCR analysis software quality threshold of 0.65 was considered for the analysis. Columns and 
rows show individual cells and the target genes assayed, respectively. N means no template control. 
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as a control (Figure 3.8). Differences in the gene expression were confirmed between the cell lines, and 
CD45 was only detected in WBCs. The list of genes used in the single-cell qRT-PCR experiment is 
presented in Table 3.3. To explore associations among different cell groups, the data were analyzed 
using unsupervised hierarchical clustering (Figure 3.6a). It is obvious that individual cells show 
heterogeneous gene expression profiles, while single cells from the same group are clustered together, 
which implies a higher degree of interpatient heterogeneity of CTCs. In addition, the t-SNE analysis, 
shown in Figure 3.6b, clearly presents the inter-cell line and interpatient heterogeneity of CTCs. A 
correlation matrix plot showing Spearman’s correlation coefficient among 30 baseline CTCs isolated 
from three patients, five WBCs, and 20 cells from the four different NSCLC cell lines (H2228, H460, 
HCC78, and PC9) is shown in Figure 3.9. 
 
We further characterized an epithelial or mesenchymal signature of individual CTCs, based on 
previous reports 116-118. Epithelial CTCs showed high levels of the epithelial marker EpCAM and CK 
markers, KRT7, KRT18, and KRT19, and low levels of mesenchymal markers, vimentin and CD44, 
whereas mesenchymal CTCs expressed the opposite trend. Individual cells from the four different 
NSCLC cell lines and three different patients with NSCLC showed different E/M hybrid signatures 
(Figure 3.6c and Figure 3.10a). Based on the classification criteria, the H2228 cell line had an M-score 
of 66.0% ± 0.7%, which was consistent with its reported EMT properties 119. The HCC78 and PC9 cell 
lines had the highest expression ratios of the epithelial markers, 95.2% ± 6.3% and 85.0% ± 2.9%, 
respectively. The H460 cell line had an intermediate expression ratio, with an M-score of 52.2% ± 8.5%. 
Despite their heterogeneity, single cells from the same cell lines were clustered together when we 
plotted the gene expression of the mesenchymal markers, vimentin and CD44, against that of the 
epithelial markers, EpCAM, KRT7, KRT18, and KRT19 (Figure 3.11). 
 
Further, distinct differences in gene expression patterns among single CTCs from the three patients 
were clearly more significant than the heterogeneity found among individual CTCs isolated from each 
patient. Five CTCs from patient LP25 mainly exhibited the epithelial signature, whereas seven CTCs 
from patient LP38 were mesenchymal. On the other hand, 18 CTCs from patient LP39 were more 
heterogeneous, with the intermediate expression of mesenchymal markers (Figure 3.6c and Figure 
10a). High expression of EMT markers is known to be characteristic of more aggressive CTCs 120. 
Although the number of samples was very limited in this exploratory study, patient LP38, whose CTCs 
showed the highest mesenchymal gene expression, had the shortest survival, whereas patient LP25, 
whose CTCs mainly showed epithelial characteristics, had the longest survival. The survival periods of 











Figure 3.8. Single-cell real-time PCR using patient-driven CTCs from baseline samples and white 
blood cells. Single-cell mRNA expression of CTCs from three different patients at baseline (LP25, 
LP38, and LP39) determined using BiomarkHD qRT-PCR with five WBCs. Columns and rows show 




Table 3.3. Genes used to profile single CTCs. 48.48 dynamic array microfluidic qRT-PCR chips 
(Fluidigm) used to confirm the expression of genes in all captured single cells. 
ALK Anaplastic lymphoma kinase, CD246 
B7-H3 CD276 
CCNB1 Cyclin B1 
CCND1 Cyclin D1 
CD133 CD133 antigen, prominin-1 
CD24 CD24 antigen 
CD34 CD34 molecule 
CD44 CD44 antigen 
CD45 PTPRC; protein-tryosine phosphatase, receptor-type, C; leukocyte-common antigen 
CDX2 Homeobox protein 
CEACAM5 Carcinoembryonic antigen-related cell adhesion molecule 5; carcinoembryonic antigen (CEA) 
c-MET MET protooncogene; hepatocyte growth factor receptor (HGFR) 
E-cadherin CDH1; E-cadherin; liver cell adhesion molecule (LCAM) 
EGFR Epidermal growth factor receptor; HER1; ERBB1 
EpCAM Epithelial cellular adhesion molecule; tumor-associated calcium signal transducer (TACSTD1) 
ERa Estrogen receptor 1; estrogen receptor, alpha (ER-a), ESR1 
ERBB2 HER2; V-ERB-B2 avian erythroblastic leukemia viral oncogene homolog 2; NEU 
FCGR3A/B Low affinity immunoglobulin gamma Fc region receptor III, CD16a/b 
FGFR1 Fibroblast growth factor receptor 1 
FOXA1 Forkhead box A1; hepatocyte nuclear factor 3-alpha (HNF3A) 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
hTERT Telomerase reverse transcriptase 
Ki67 MKI67, marker of proliferation Ki-67 
KIT Proto-oncogene c-Kit, CD117 
KRAS K-ras, KRAS proto-oncogne 
KRT18 Kerain 18; cytokeratin 18 
KRT19 Keratin 19 
71 
  
KRT20 Keratin 20 
KRT7 Keratin 7 
KRT8 Keratin 8; cytokeratin 8 
MMP12 matrix metalloproteinase-12 
MMP7 matrix metalloproteinase-7 
MUC1 Mucin 1, transmembrane 
MUC2 Mucin 2 
NANOG Nanog homeobox 
N-cadherin CDH2; neural cadherin (NCAD) 
NRAS Neuroblastoma RAS viral oncogene homolog 
p53 Tumor protein p53, transformation-related protein 53(TRP53) 
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha 
PSA Prostate-specific antigen 
PSMA prostate-specific membrane antigen, folate hydrolase 1(FOLH1) 
PTEN Phosphatase and tensin homolog 
Survivin Baculoviral IAP repeat-containing protein 5; apoptosis inhibitor 4 (API4); BIRC5 
TGFB1 Transforming growth factor, beta-1 
TWIST1 Twist, drosophila, homolog of 1 









Figure 3.9. Correlation matrix plots of correlations among 20 cells from four different cancer cell 
lines, five WBCs, and 30 patient-derived baseline CTCs isolated from three different patients. 
Spearman correlation coefficients for sample characteristics. High and low similarity is indicated with 
blue and red color based on the scale bar, respectively. The circle size represents the magnitude of the 
correlation. P-values in this correlation analysis were derived using the Cor.mtest function in R. 









Figure 3.10. Summary of mesenchymal scores. (a) Distribution of mesenchymal scores from each 
sample according to the EMT characterization among four NSCLC cell lines and three NSCLC patients. 





Figure 3.11. Correlation of marker expression among four NSCLC cell lines. (a) Vimentin 
expression of five cells from each cell line according to the expression of epithelial markers EpCAM, 
KRT7, 18, and 19, respectively. (b) CD44 expression of five cells from each cell line according to the 




Serial monitoring of single-cell RNA expression in CTCs from patients with NSCLC during 
EGFR-TKI treatment 
For treatment response monitoring using CTCs, we performed a single-cell-level mRNA gene 
expression analysis using individual CTCs isolated at three time points during chemotherapy, in 
addition to regular measurements of CTC counts and CT image responses. For this proof of concept 
study, we enrolled two prospective patients, LP25 (Figure 3.12) and LP38 (Figure 3.13), during the 
period of EGFR-TKI (afatinib) treatment. 
 
In the case of patient LP25, the initial treatment response was relatively good, and the number of 
CTCs/7.5 mL of blood decreased from 57.5 at baseline to 2.5 after 159 days of treatment, which was 
consistent with the CT scan-based SD and PR statuses after 30, 90, and 180 days of treatment, as shown 
in Figure 3.12a. However, the CTC counts increased to 15.0, 67.5, and 195.0 per 7.5 mL after 187, 250, 
and 281 days of treatment, which was in good agreement with radiographic data, indicating PD, at 282 
days of treatment. 
 
In contrast, patient LP38 showed 67.5 CTCs/7.5 mL at baseline, but the counts decreased to 12.5, 
25.0, 5.0, and 15.0 at 71, 120, 155, and 196 days of treatment, respectively. Although the patient initially 
showed an SD response, until 120 days of treatment, the tumor size increased again, scoring PD, at 196 
days, and the patient died 211 days after entering the study. 
 
Although the dynamic changes in the numbers of CTCs were overall consistent with the CT data 
and clinical outcomes, the CTC counts were not sufficient to predict clinical outcomes. We 
hypothesized that, in addition to the total number of CTCs, the heterogeneity of individual CTCs and 
their characteristics might affect the patient outcome. Therefore, we tracked the gene expression 
characteristics of individual CTCs during the time course of TKI therapy. 
 
For patient LP25, the single-cell-level gene expression profiling was performed using 5, 17, and 
20 CTCs isolated before (LP25-0), after 250 days (LP25-8), and after 281 days (LP25-9) of treatment, 
respectively (Figure 3.12 and Figure 3.14). From patient LP38, 7, 17, and 22 CTCs were isolated 
before (LP38-0), after 120 days (LP38-3), and after 155 days (LP38-4) of treatment, respectively 
(Figure 3.13 and Figure 3.15). The numbers of CTCs used for the gene expression analysis (Figure 
3.12b–d and Figure 3.13b–d) did not reflect the total numbers of CTCs, which were more carefully 
enumerated using an additional blood sample, as shown in Figure 3.12a and Figure 3.13a. As shown 
in the 3D t-SNE plots in Figure 3.12c and Figure 3.13c, each individual CTC showed a different gene 
expression pattern in hierarchical clustering, but CTCs from the same time point were well clustered 




Figure 3.12. Longitudinal study of LP25 with CTC counts, individual CTC profile, and CT image 
response during TKI therapy. (a) Correlation between the number of CTCs and tumor size from CT 
images in patient LP25 with EGFR-mutant NSCLC during the course of TKI therapy. (b) Heatmap of 
the hierarchical clustering of gene expression profiles of single CTCs. (c) Three-dimensional t-SNE 
plots for CTCs isolated at three time points during the therapy of patient LP25. Despite the inter-sample 
heterogeneity of CTCs, cells clustered according to the same time point during the treatment. (d) EMT 




Figure 3.13. Longitudinal study of patient LP38 with CTC counts, individual CTC profile, and 
CT image response during TKI therapy. (a) Correlation between the number of CTCs and tumor size 
from CT images in patient LP38 with EGFR-mutant NSCLC during the course of TKI therapy. (b) 
Heatmap of the hierarchical clustering of gene expression profiles of single CTCs. (c) Three-
dimensional t-SNE plots for CTCs isolated at three time points during the therapy of patient LP38. 
Despite the inter-sample heterogeneity of CTCs, the cells clustered according to the same time point 









Figure 3.14. Single-cell real-time PCR using CTCs from patient LP25 at various time points. 
Single-cell mRNA expression was determined using BiomarkHD qRT-PCR. Columns and rows show 









Figure 3.15. Single-cell real-time PCR using CTCs from patient LP38 at various time points. 
Single-cell mRNA expression was determined using BiomarkHD qRT-PCR. Columns and rows show 
individual cells and the target genes assayed, respectively. N means no template control. 
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In addition, the gene expression profiles of CTCs isolated at different time points were distinctly 
different, which was also demonstrated by the correlation matrix analysis (Figure 3.16 and Figure 
3.17). 
 
We further characterized the EMT signatures of individual CTCs isolated during the time course 
of therapy. As shown in Figure 3.12a, patient LP25 showed SD and PR based on the CT scan results 
until 180 days, but the status changed to PD because of a new brain lesion at 282 days (LP25-9). 
Interestingly, the LP25-9 CTCs showed much higher expression of many more genes than did the LP25-
0 or LP25-8 CTCs. When we classified individual CTCs based on the epithelial or mesenchymal gene 
expression signature, the heterogeneity of individual CTCs, as well as the dynamic change of the M-
score, was obvious, as shown in Figure 3.12d. The M-score of CTCs at baseline (LP25-0) was relatively 
low (22.06% ± 12.96%) but increased, with a large standard deviation (49.53% ± 24.80%), for CTCs 
isolated after 250 days (LP25-8), which was approximately 1 month before PD was scored, with a new 
lesion in the brain. Interestingly, CTCs obtained on day 282, which was when a CT scan was taken, and 
PD was scored (LP25-9), showed a slightly decreased M-score, with a much lower intra-sample 
heterogeneity (37.51% ± 4.96%; Figure 3.10b). 
 
Patient LP38 had the highest expression of many genes in baseline CTCs (LP38-0), which 
somewhat decreased in CTCs isolated after 120 days of treatment (LP38-3), but with a significantly 
enhanced heterogeneity (Figure 3.13d and Figure 3.10c). Likewise, the tumor size was the largest at 
LP38-0 and decreased by 22% as the target lesion was scored SD (LP38-3). However, CTCs isolated 
after 155 days of treatment (LP38-4) again showed increased gene expression signals, which was 
consistent with the future clinical outcome and a PD score after 196 days of treatment. The EMT 
signature of individual CTCs was the strongest (82.39% ± 4.61%) at baseline (LP38-0), which 
dramatically decreased, with a high heterogeneity (39.24% ± 18.30%), in the LP38-3 CTCs and then 
remained at a similar level but with a lower heterogeneity (42.09% ± 8.31%) in the LP38-4 CTCs. 
Unfortunately, the amount of the blood sample obtained on day 196 was not sufficient for single-cell 








Figure 3.16. Correlation matrix plots of CTCs before and after treatment in patient LP25. 
Spearman correlation coefficients for sample characteristics. High and low similarity is indicated with 









Figure 3.17. Correlation matrix plots of CTCs before and after treatment in patient LP38. 
Spearman correlation coefficients for sample characteristics. High and low similarity is indicated with 






The availability of more facile methods for measuring the disease progression and identifying 
predictive biomarkers of therapeutic responses in patients with NSCLC would significantly contribute 
to clinical outcomes of patients. Recent advances in liquid biopsy technologies have enabled less 
invasive access to tumor materials, highlighting the prognostic value of CTCs in disease management 
121-125. However, frequent monitoring of CTCs has been limited by inconsistency in the enrichment yield 
of the extremely rare and heterogeneous cells, as well as by high costs and complexity of experimental 
protocols. Our study of prospectively collected blood samples from patients with NSCLC before and 
during EGFR-TKI therapy showed that longitudinal analysis of CTCs enumerated using a label-free 
isolation approach might provide early access to monitoring disease responses to targeted therapy. 
 
Many studies have demonstrated that pretreatment CTC counts are highly relevant to PFS or OS 
of patients with advanced NSCLC 28, 95. However, there have also been conflicting reports showing no 
statistical significance in the survival outcome depending on baseline CTC counts 100, 101. A likely 
explanation for this discrepancy is the lack of standard enumeration methods for extremely rare and 
heterogeneous CTCs, as well as differences in the type of patients and the choice of treatment options. 
In our study, CTCs were detected in the majority of patients (85%), but the baseline CTC counts did 
not show an association with PFS or OS. On the other hand, dynamic changes in CTC counts were 
associated with CT scan-based tumor responses, suggesting a potential utility for early identification of 
responses to therapies. Although our data are consistent with those of a previous report 126, the number 
of patients was limited, and a further study, with a larger number of prospective patients in a setting 
with other targeted therapies or chemotherapy, is required to validate these findings. 
 
Frequent monitoring of tumor mutations in patients with lung cancer is an urgent need to provide 
a clinically important guidance for disease management 36, 127-129. For most patients with NSCLC, who 
harbor EGFR mutations, the treatment with an EGFR-TKIs therapy is beneficial. However, the T790M 
point mutation may arise soon, indicating the development of resistance to EGFR-TKI and the necessity 
to change the drug to third-generation EGFR-TKIs. Tissue biopsy is highly invasive, which prevents 
frequent monitoring of the development of mutations, and may not provide a representative mutation 
profile for patients with heterogeneous tumors at multiple sites. In this study, we demonstrated 100% 
concordance in the detection of EGFR mutations in tumor tissue and CTCs isolated from a total of 15 
samples collected from 13 patients, including two cases of the emergence of the T790M mutation. These 
results present a promising outlook on the potential of routine analysis of CTCs to provide clinically 




Other molecular information, such as gene expression data, can also be obtained by downstream 
analysis of a single CTC. Direct analysis of bulk cells may generate background signals from WBCs 
and other blood cells 130. Furthermore, bulk cell-level analysis, based on signal averaging, leads to losing 
individual characteristics of heterogeneous CTCs, which are related to tumor biology and metastatic 
potential 131. The importance of CTC characterization at a single-cell level has been highlighted by 
profiling multigene expression in individual CTCs in a heterogeneous population 102, 128, classifying 
CTC subpopulations 114, and studying an association of CTCs with the clinical outcome or tumor 
biology 132. Herein, by using a label-free, high-throughput, clinical setting-friendly method for CTC 
isolation, based on the previously reported tabletop-sized FAST disc system 108, we were able to perform 
a longitudinal analysis of single-cell gene expression in CTCs isolated before and during targeted 
therapy. Our findings from single-cell gene expression analysis of four different lung cancer cell lines 
and three different patients indicated that the inter-heterogeneity among different cell lines or patients 
was much higher than the intra-heterogeneity within each group of CTCs. 
 
EMT plays a key role in tumor progression and metastasis. EMT is associated with the loss of the 
epithelial phenotype, and increased invasion, migration, and cell proliferation are associated with the 
increased expression of mesenchymal markers. A number of studies have suggested that EMT may be 
associated with the resistance to EGFR-TKIs in patients with NSCLC 133, 134. It was also suggested, 
based on liquid biopsy applications, that CTCs expressing EMT-related genes were associated with the 
disease progression and poor therapeutic responses in patients with breast 116, gastric 117, pancreatic 114, 
and lung 135 cancer. Gene expression in single cells has been studied to evaluate the heterogeneity of 
individual CTCs. Thus, Lin et al. 118 characterized single CTCs and demonstrated their inter- and intra- 
patient heterogeneity in four patients with pancreatic cancer. Ting et al. 136 conducted single-cell RNA 
sequencing of pancreatic CTCs and identified three distinct populations, with the data suggesting 
multiple pathways in the metastatic cascade. However, molecular analysis of single CTCs remains 
challenging because currently available platforms are expensive and not robust enough to be translated 
into the clinic. Consequently, there have been no reports on longitudinal monitoring of therapeutic 
responses via profiling of the EMT signature in individual CTCs based on a single-cell gene expression 
analysis. 
 
EMT is crucial for cancer cells to acquire invasive and migratory abilities, eventually driving tumor 
metastasis. Recent studies have reported that EMT is not a step function, in which the change occurs 
from the E to the M state and that cells rather exhibit a hybrid E/M phenotype with a mix of E/M traits, 
which may be highly correlated with patient outcomes 134, 137, 138. One important result of this study was 
that the E/M signature scores obtained by multigene expression analysis of single cells revealed 
substantial heterogeneity among individual cells and among cell lines. Despite their relatively small 
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intra-heterogeneity, the EMT scores of individual cells from four different NSCLC cell lines could 
predict the known characteristics of the specific cell types, which were categorized as mainly 
mesenchymal or epithelial, or a hybrid state, showing both traits 134, 139, 140. Furthermore, analysis of 
EMT scores of individual pretreatment CTCs isolated from three patients with NSCLC indicated that 
the patients who showed relatively poor drug responses had CTCs with high M-scores, while the patient 
who showed a relatively good response to EGFR-TKI therapy had CTCs with high E-scores. Despite 
the heterogeneity in multigene expression and EMT scores among CTCs isolated from the patients, 
CTCs from the same source were clustered together, suggesting that the interpatient heterogeneity was 
higher than the intra-patient one. 
 
We also monitored how multigene expression and EMT signatures evolved during EGFR-TKI 
therapy. Based on the data obtained using a limited number of CTCs isolated from two patients, the 
EMT scores of pretreatment CTCs were better associated with the drug response than were those of 
CTCs obtained during EGFR-TKI therapy. Even though the EMT scores of pretreatment CTCs were 
distinctly different (predominantly E or M), the EMT signatures of individual CTCs became more 
heterogeneous and then changed to a relatively uniform E/M hybrid signature during EGFR-TKI 
treatment. However, the meaning of the change in multigene expression profiles should be further 
validated in relation to drug responses in future studies, involving large cohorts of patients.  
 
Although we only performed gene expression analysis using the Fluidigm technology, CTCs 
isolated without antibody selection bias can be applied for other types of molecular analysis at a single-
cell level to unveil the tumor heterogeneity during disease progression upon personalized therapy. 
Despite the significantly reduced turnaround time and minimized manual operation steps, the CTC 
counting and picking process still require manual operation, which need to be automated for broader 
usage in clinical settings. A potentially important application of our technology is the isolation of CTC 
clusters, which are emerging as important players in metastasis. Though we could frequently observe 
CTC clusters from patients with other types of cancer, CTC clusters were rarely observed from patients 
with NSCLC (Figure 3.2b). In recent studies on inertial microfluidics-based CTC isolation using blood 
samples from patients with NSCLC, Zhou et al. did not observe CTC clusters 106, while Zeinali et al. 
detected CTC clusters from the majority of patients 107. We believe that this discrepancy might be due 
to the different cohort of patients with relatively limited number of clinical samples. 
 
In conclusion, we demonstrated that the label-free and clinical setting-friendly FAST disc platform 
enabled rapid enumeration of CTCs and their unbiased molecular analysis at a single-cell level. Our 
approach can be readily applied in future clinical studies for early detection of actionable mutations for 
therapy selection and disease monitoring. Our findings from an exploratory, small-scale, prospective 
86 
  
cohort study of EGFR-mutant patients with NSCLC support the importance of single-cell-level 
molecular analysis, including an EMT signature, to investigate the dynamics of disease progression and 
predict the drug response. We anticipate that the FAST disc system can become a clinical research tool 
to achieve comprehensive molecular profiling and assess the heterogeneity of CTCs from patients 
undergoing targeted therapy and to monitor the association with clinical outcomes. Overall, high-
throughput, label-free isolation of CTCs from whole blood using the FAST disc platform may facilitate 
minimally invasive characterization and frequent monitoring of tumor progression for timely selection 




Chapter 4. General conclusions and future perspectives 
4.1 General conclusions 
Here, we demonstrated that the clog-free FAST disc platform enabled ultrafast enumeration of 
intact CTCs and their unbiased molecular analysis at a single-cell level. First of all, a robust centrifugal 
microfluidic platform, FAST disc, was developed and it can be used for the CTC enrichment from 
whole blood samples without clogging-issue. FAST disc achieved high sensitivity (95.9 ± 3.1% 
recovery rate) and selectivity (>2.5 log depletion of white blood cells), with rapid (>3 mL/min) 
operation. The results of numerical simulation and experiments supported that FAST disc provided 
clog-free uniform and rapid cell enrichment with much less pressure drops (1 kPa) than in the 
conventional size-based filtration. The utility of the point-of-care detection of CTCs with clinical 
samples was validated with 142 patients suffering from breast, stomach, or lung cancer. 
Furthermore, a CTC-based liquid biopsy approach was used to examine the response of therapy 
and demonstrated the discovery of emergent drug resistance by longitudinal monitoring in a prospective 
cohort of 40 EGFR-mutant NSCLC patients with CTC counts, DNA mutations, and single-cell level 
gene expression. The change ratio of the CTC counts, based on each CTC count at baseline according 
to the patients, was significantly associated with clinical outcome which defined by CT scan images 
while the baseline CTC counts did not have any association with progression-free survival or overall 
survival. The detection of EGFR mutation was achieved a 100% concordance rate between tumor tissue 
and CTCs including emergence of T790M. Moreover, the data of mRNA profiling revealed the 
importance of the analysis to the epithelial/mesenchymal signature of individual CTCs to predict the 
response of drug in patients. The FAST disc enabled serial monitoring based on CTC counts, DNA 
mutations, as well as unbiased molecular characterization of patient-driven CTCs associated with tumor 
progression in NSCLC during targeted therapy. 
Overall, our approach can be applied to future clinical studies for disease monitoring and early 
detection of actionable mutations related with therapy selection. From an exploratory, small-scale, 
prospective cohort study of EGFR-mutant NSCLC patients, our findings support the importance of 
single-cell level molecular analysis, including an EMT signature, to study the dynamics of disease 
progression and predict the drug responsiveness. We expect that the FAST disc can become a tool for 
clinical research to achieve comprehensive molecular profiling and investigate the heterogeneity of 
CTCs according to the patients who undergo targeted therapy and to predict the clinical outcomes based 
on the association with CTCs. High-throughput, label-free CTC isolation from whole blood using the 
FAST disc platform may induce frequent monitoring of tumor progression for timely selection of a 
personalized medicine via minimally invasive characterization. 
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4.2 Plan for future 
In this thesis, we focus on the NSCLC as the application field of CTC based liquid biopsy. Another 
applicable field would be a pancreatic cancer due to its high incidence and mortality rate. Moreover, 
there is no specific marker for pancreatic cancer yet so CTCs are expected as a clue to understand 
unrevealed characteristics of pancreatic cancer. 
Pancreatic cancer is a 5th leading cause of cancer mortality in Korea and a 4th leading cause in the 
United States 141-143. Pancreatic cancer showed a dismal prognosis with a 5-year survival rate of below 
9 % because most patients are detected in the late phase due to its characteristics such as rapid 
progression and early metastasis 144, 145. Although recent advancements of therapeutic options such as 
FOLFIRINOX and nab-paclitaxel, pancreatic cancer may be refractory to these chemotherapeutic 
agents and rapidly progress resulting in early death. Therefore, better prognostic biomarkers are needed 
to select good candidates for chemotherapy in patients with unresectable pancreatic cancer. 
CTCs are good candidates for prognostic biomarkers because these enable frequent analysis less 
invasively and provides the chance to study real-time dynamics of cancer. Although the efficient 
technologies for CTC analysis have been remarkably developed since 2007 146-148, the isolation and 
characterization of CTCs are still challenging due to their rarity and heterogeneity and away from real-
world use for evaluating the relationship between CTCs and clinical outcomes 149-152.  
A few papers reported the significant relationship between CTC counts and survival in pancreatic 
cancer 153. However, conventional CTC detection based on epithelial markers had limitation to detect 
heterogeneous pancreatic CTCs. Additional marker expression in pancreatic CTCs, including 
mesenchymal markers or stemness markers, were studied with survival 149, 154. 
Moreover, few papers reported a heterogeneous gene expression of patient-driven CTCs in 
pancreatic cancer 114, 155, 156. D.T. Ting et al characterized CTCs by dividing subgroup (classical CTC, 
platelet marker expressed CTC and proliferative CTC) based on the results of single cell RNA 
sequencing 155. M. Lapin et al studied the subpopulation of CTCs according to the expression level of 
mRNA related to CTC phenotype 114. C. Amantini et al found the change of marker expression among 
19 genes according to treatment 156. These reports contributed to understanding the characteristics of 
individual CTCs. But, advanced analysis with diverse aspects is required to extensive understand for 
heterogeneous CTC in pancreatic cancer. 
One of the aspects is formation of CTCs. Formation of CTCs could be single CTCs or CTC clusters 
in circulation. The laters are interacting with circulating cells such as platelets, neutrophils, 
macrophages, and fibroblasts which are related to poor prognosis in various types of cancer. B.M. 
Szczerba et al reported the role of neutrophils in CTC cluster related to the metastatic potential in breast 
cancer 157. However, the comprehensive characterization of the CTC clusters remains unknown. 
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Hereafter, downstream analysis of single CTCs and CTC clusters from each patient is needed for 
observing distinct characteristics related to clinical outcomes. Therefore, a robust CTC isolation system 
with high efficacy and a high-throughput molecular analysis of CTCs become increasingly necessary. 
Our robust FAST disc enables a comprehensive characterization of CTCs through mRNA profiling 
by multiplex PCR with 48 RNA markers which already has been used to report about single CTCs and 
CTC clusters analysis 132, 158, 159. 
We will investigate a strategy for the isolation of single CTCs and CTC clusters by FAST disc and 
the phenotypic characterization of CTC clusters based on mRNA profiling and demonstrate the 
correlation between mRNA expression of CTC clusters and clinical outcomes in patients with 




4.3 Future perspective 
 
Active collaborations between clinics and academic research are necessary for clinical validation 
of new technologies for liquid biopsy. In this thesis, we suggest a robust device for CTC isolation which 
can be expected to expand the ability to utilize CTC based liquid biopsy in clinical routine and 
longitudinal surveillance of cancer therapy. If it is applied to run multicenter-large scale clinical trials, 
FAST disc can serve to clarify the clinical utility of CTCs in clinical routine. 
 
For improving precision medicine, common implementation of single-cell analysis about CTC 
heterogeneity in clinical routine will be feasible with accompanying development of the technologies 
which can solve the problem of existing methods for molecular analysis, such as high cost and time-
consuming process. Actualization of single-cell analysis will contribute to make affordable precision 
medicine for many patients. 
 
On the other side, study about the relationship with other liquid biopsy markers, such as ctDNA 
and extracellular vesicle, allow better understanding of cancer progression and metastasis mechanism. 
For clinical applications, complementary use of multi-markers may be beneficial to improve the 
predictive accuracy in diagnostic and prognostic and to enhance the sensitivity and specificity of liquid 
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